US20190048349A1

US20190048349A1 - Aptamers for oral care applications

Info

Publication number: US20190048349A1
Application number: US16/059,597
Authority: US
Inventors: Juan Esteban Velasquez; Amy Violet Trejo; Paul Albert Sagel; Gregory Allen Penner
Original assignee: Procter and Gamble Co
Current assignee: Procter and Gamble Co; NeoVentures Biotechnology Inc
Priority date: 2017-08-09
Filing date: 2018-08-09
Publication date: 2019-02-14
Also published as: JP2020529444A; AU2018316205A1; CN111032870A; EP3664776A1; MX2020001299A; US20190048348A1; BR112020002558A2; CA3069933A1; WO2019032795A1; CN111050745A; EP3665282A1; WO2019032811A1; US10676748B2

Abstract

An aptamer composition is disclosed which has one or more oligonucleotides that include at least one of deoxyribonucleotides, ribonucleotides, derivatives of deoxyribonucleotides, derivatives of ribonucleotides, or mixtures thereof. The aptamer composition has a binding affinity for a material that is at least one of tooth, enamel, dentin, carbonated calcium-deficient hydroxyapatite, or mixtures thereof.

Description

FIELD OF INVENTION

The present invention generally relates to nucleic acid aptamers that have a high binding affinity and specificity for teeth. This invention also relates to the use of such aptamers as delivery vehicles of active ingredients to the oral cavity.

BACKGROUND OF THE INVENTION

Aptamers are short single-stranded oligonucleotides, with a specific and complex three-dimensional shape, that bind to target molecules. The molecular recognition of aptamers is based on structure compatibility and intermolecular interactions, including electrostatic forces, van der Waals interactions, hydrogen bonding, and π-π stacking interactions of aromatic rings with the target material. The targets of aptamers include, but are not limited to, peptides, proteins, nucleotides, amino acids, antibiotics, low molecular weight organic or inorganic compounds, and even whole cells. The dissociation constant of aptamers typically varies between micromolar and picomolar levels, which is comparable to the affinity of antibodies to their antigens. Aptamers can also be designed to have high specificity, enabling the discrimination of target molecules from closely related derivatives.
Aptamers are usually designed in vitro from large libraries of random nucleic acids by Systematic Evolution of Ligands by Exponential Enrichment (SELEX). The SELEX method was first introduced in 1990 when single stranded RNAs were selected against low molecular weight dyes (Ellington, A. D., Szostak, J. W., 1990. Nature 346: 818-822). A few years later, single stranded DNA aptamers and aptamers containing chemically modified nucleotides were also described (Ellington, A. D., Szostak, J. W., 1992. Nature 355: 850-852; Green, L. S., et al., 1995. Chem. Biol. 2: 683-695). Since then, aptamers for hundreds of microscopic targets, such as cations, small molecules, proteins, cells, or tissues have been selected. A compilation of examples from the literature is included in the database at the website: http://www.aptagen.com/aptamer-index/aptamer-list.aspx. However, a need still exists for aptamers that selectively bind to surfaces in the oral cavity, including teeth.

SUMMARY OF THE INVENTION

In this invention, we have demonstrated the use of SELEX for the selection of aptamers against teeth and the use of such aptamers for the delivery of active ingredients to the oral cavity.
In certain embodiments of the present invention, an aptamer composition is provided. The aptamer composition comprises at least one oligonucleotide which may include: deoxyribonucleotides, ribonucleotides, derivatives of deoxyribonucleotides, derivatives of ribonucleotides, or mixtures thereof; wherein said aptamer composition has a binding affinity for a material selected from the group consisting of: tooth, enamel, dentin, carbonated calcium-deficient hydroxyapatite, and mixtures thereof.
In another embodiment of the present invention, an aptamer composition is provided. The aptamer composition including at least one oligonucleotide comprising SEQ ID NO 1, SEQ ID NO 9, SEQ ID NO 25, SEQ ID NO 112, SEQ ID NO 120, SEQ ID NO 136, or SEQ ID NO 223 to SEQ ID NO 234.
In another embodiment of the present invention, an aptamer composition includes at least one oligonucleotide having one or more motifs comprising SEQ ID NO 235, SEQ ID NO 236, SEQ ID NO 237, SEQ ID NO 238, SEQ ID NO 239, SEQ ID NO 240, SEQ ID NO 241, SEQ ID NO 242, SEQ ID NO 243, or SEQ ID NO 244.
In another embodiment of the present invention, an oral care composition is provided. The oral care composition comprises at least one nucleic acid aptamer; wherein said at least one nucleic acid aptamer has a binding affinity for an oral cavity component. In another embodiment of the present invention, said oral cavity component comprises at least one of: tooth, enamel, dentin, or any other surfaces in the oral cavity. In yet another embodiment, said oral cavity component is tooth.
In another embodiment of the present invention, a method for delivering one or more oral care active ingredients to the oral cavity is provided. The method comprises administering an oral care composition comprising at least one nucleic acid aptamer and one or more oral care active ingredients; wherein said at least one nucleic acid aptamer and said one or more oral care active ingredients are covalently or non-covalently attached; and wherein said at least one nucleic acid aptamer has a binding affinity for an oral cavity component.
In another embodiment of the present invention, a method for delivering one or more oral care active ingredients to the oral cavity is provided. The method comprises administering an oral care composition comprising: at least one nucleic acid aptamer and one or more nanomaterials; wherein said at least one nucleic acid aptamer and said one or more nanomaterials are covalently or non-covalently attached; and wherein said at least one nucleic acid aptamer has a binding affinity for an oral cavity component.

BRIEF DESCRIPTION OF THE DRAWINGS

For a more complete understanding of the disclosure, reference should be made to the following detailed description and drawing FIGS.

FIG. 1 illustrates the enrichment trajectories of the top twenty sequences in terms of copy number across different selection rounds for Experiment A.

FIG. 2 illustrates the enrichment trajectories of the top twenty sequences in terms of copy number across different selection rounds for Experiment B.

FIG. 3A shows a negative control.

FIG. 3B shows the binding of the aptamer identified as “OC1R-B1” to teeth.

FIG. 3C shows the binding of the aptamer identified as “OC1R-B9” to teeth.

FIG. 3D shows the binding of the aptamer identified as “OC1R-B25/OC1R-A9” to teeth.

FIG. 4 illustrates the correlation matrix ordered by clustering (Ward.D2 method) for enrichment trajectories of the top 100 sequences in terms of copy number for Experiment B.

FIG. 5 illustrates the results of the motif analysis of random region of aptamer OC1R-B1.

FIG. 6 illustrates the predicted secondary structure of aptamer OC1R-B1 and its conserved motif.

FIG. 7 illustrates the results of the motif analysis of random region of aptamer OC1R-B9.

FIG. 8 illustrates the predicted secondary structure of aptamer OC1R-B9 and its conserved motifs.

FIG. 9 illustrates the results of the motif analysis of random region of aptamer OC1R-A9.

FIG. 10 illustrates the predicted secondary structure of aptamer OC1R-A9 and its conserved motif.

FIG. 11 illustrates the predicted secondary structure of aptamer OC1D-A9.

FIG. 12 illustrates the alignment of exemplary sequences with at least 90% nucleotide sequence identity that were identified during the selection process.

FIG. 13 illustrates the alignment of exemplary sequences with at least 70% nucleotide sequence identity that were identified during the selection process.

FIG. 14 illustrates the alignment of exemplary sequences with at least 50% nucleotide sequence identity that were identified during the selection process.

FIG. 15 illustrates the amount of DNA Aptamers bound to teeth.

FIG. 16 illustrates the amount of DNA Aptamers bound to teeth after every washing.

FIG. 17 illustrates the total amount of DNA aptamers bound (remaining), washed (eluted), and unrecovered (lost) from teeth.

FIG. 18A illustrates the predicted secondary structures of aptamer OC1D-B1.

FIG. 18B illustrates the predicted secondary structures of aptamer OC1D-B1.1.

FIG. 18C illustrates the predicted secondary structures of aptamer OC1D-B1.2.

FIG. 18D illustrates the predicted secondary structures of aptamer OC1D-B1.3.

FIG. 19A illustrates the predicted secondary structure of aptamer OC1D-B9.

FIG. 19B illustrates the predicted secondary structure of aptamer OC1D-B9.1.

FIG. 19C illustrates the predicted secondary structure of aptamer OC1D-B9.2.

FIG. 20A illustrates the predicted secondary structure of aptamer OC1D-A9.

FIG. 20B illustrates the predicted secondary structure of aptamer OC1D-A9.1.

FIGS. 21A-C illustrate the binding of truncated DNA aptamers to teeth.

DETAILED DESCRIPTION OF THE INVENTION

The present invention includes oral care compositions comprising one or more aptamers, wherein the aptamers are designed to bind to specific targets within the oral cavity, such as tooth surfaces or mucosal tissue. Oral care actives may be bound to the aptamers allowing the actives to be delivered to the specific oral cavity target, allowing for greater efficiency and affect.

Definitions

As used herein, the term “aptamer” refers to a single stranded oligonucleotide or a peptide that has a binding affinity for a specific target.
As used herein, the term “nucleic acid” refers to a polymer or oligomer of nucleotides. Nucleic acids are also referred as “ribonucleic acids” when the sugar moiety of the nucleotides is D-ribose and as “deoxyribonucleic acids” when the sugar moiety is 2-deoxy-D-ribose.
As used herein, the term “nucleotide” usually refers to a compound consisting of a nucleoside esterified to a monophosphate, polyphosphate, or phosphate-derivative group via the hydroxyl group of the 5-carbon of the sugar moiety. Nucleotides are also referred as “ribonucleotides” when the sugar moiety is D-ribose and as “deoxyribonucleotides” when the sugar moiety is 2-deoxy-D-ribose.
As used herein, the term “nucleoside” refers to a glycosylamine consisting of a nucleobase, such as a purine or pyrimidine, usually linked to a 5-carbon sugar (e.g. D-ribose or 2-deoxy-D-ribose) via a β-glycosidic linkage. Nucleosides are also referred as “ribonucleosides” when the sugar moiety is D-ribose and as “deoxyribonucleosides” when the sugar moiety is 2-deoxy-D-ribose.
As used herein, the term “nucleobase”, refers to a compound containing a nitrogen atom that has the chemical properties of a base. Non-limiting examples of nucleobases are compounds comprising pyridine, purine, or pyrimidine moieties, including, but not limited to adenine, guanine, hypoxanthine, thymine, cytosine, and uracil.
As used herein, the term “oligonucleotide” refers to an oligomer composed of nucleotides.
As used herein, the term “identical” or “sequence identity,” in the context of two or more oligonucleotides, nucleic acids, or aptamers, refers to two or more sequences that are the same or have a specified percentage of nucleotides that are the same, when compared and aligned for maximum correspondence, as measured using sequence comparison algorithms or by visual inspection.
As used herein, the term “substantially homologous” or “substantially identical” in the context of two or more oligonucleotides, nucleic acids, or aptamers, generally refers to two or more sequences or subsequences that have at least 40%, 60%, 80%, 90%, 95%, 96%, 97%, 98% or 99% nucleotide identity, when compared and aligned for maximum correspondence, as measured using sequence comparison algorithms or by visual inspection.
As used herein, the term “epitope” refers to the region of a target that interacts with the aptamer. An epitope can be a contiguous stretch within the target or can be represented by multiple points that are physically proximal in a folded form of the target.
As used herein, the term “motif” refers to the sequence of contiguous, or series of contiguous, nucleotides occurring in a library of aptamers with binding affinity towards a specific target (e.g. teeth) and that exhibit a statistically significant higher probability of occurrence than would be expected compared to a library of random oligonucleotides. The motif sequence is frequently the result or driver of the aptamer selection process.
As used herein the term “binding affinity” may be calculated using the following equation: Binding Affinity=Amount of aptamer bound to one or more teeth/Total amount of aptamer incubated with one or more teeth.
By “oral care composition”, as used herein, is meant a product, which in the ordinary course of usage, is not intentionally swallowed for purposes of systemic administration of therapeutic agents, but is rather retained in the oral cavity for a time sufficient to contact dental surfaces or oral tissues. Examples of oral care compositions include dentifrice, tooth gel, subgingival gel, mouth rinse, mousse, foam, mouth spray, lozenge, chewable tablet, chewing gum, tooth whitening strips, floss and floss coatings, breath freshening dissolvable strips, or denture care or adhesive product. The oral care composition may also be incorporated onto strips or films for direct application or attachment to oral surfaces.
The term “dentifrice”, as used herein, includes tooth or subgingival-paste, gel, or liquid formulations unless otherwise specified. The dentifrice composition may be a single phase composition or may be a combination of two or more separate dentifrice compositions. The dentifrice composition may be in any desired form, such as deep striped, surface striped, multilayered, having a gel surrounding a paste, or any combination thereof. Each dentifrice composition in a dentifrice comprising two or more separate dentifrice compositions may be contained in a physically separated compartment of a dispenser and dispensed side-by-side.
All percentages and ratios used hereinafter are by weight of total composition, unless otherwise indicated. All percentages, ratios, and levels of ingredients referred to herein are based on the actual amount of the ingredient, and do not include solvents, fillers, or other materials with which the ingredient may be combined as a commercially available product, unless otherwise indicated.
All measurements referred to herein are made at 25° C. unless otherwise specified.
As used herein, the term “oral cavity” means the part of the mouth including the teeth and gums and the cavity behind the teeth and gums that is bounded above by the hard and soft palates and below by the tongue and mucous membrane.

Aptamer Compositions

Nucleic acid aptamers are single-stranded oligonucleotides, with specific secondary and tertiary structures, that can bind to targets with high affinity and specificity. In certain embodiments of the present invention, an aptamer composition comprises at least one oligonucleotide comprising: deoxyribonucleotides, ribonucleotides, derivatives of deoxyribonucleotides, derivatives of ribonucleotides, or mixtures thereof; wherein said aptamer composition has a binding affinity for a material that is at least one of: tooth, enamel, dentin, hydroxyapatite, carbonated calcium-deficient hydroxyapatite, or mixtures thereof. In another embodiment, said aptamer composition has a binding affinity for tooth.
In another embodiment, an aptamer composition includes at least one oligonucleotide comprising oligonucleotides with at least 50% nucleotide sequence identity to sequences that are at least one of SEQ ID NO 1 to SEQ ID NO 234. In another embodiment, an aptamer composition includes at least one oligonucleotide comprising oligonucleotides with at least 70% nucleotide sequence identity to sequences including SEQ ID NO 1 to SEQ ID NO 234. In yet another embodiment, an aptamer composition comprises at least one oligonucleotide having at least 90% nucleotide sequence identity to at least one of SEQ ID NO 1 to SEQ ID NO 234. In another embodiment, an aptamer composition comprises at least one oligonucleotide having at least 20 contiguous nucleotides from at least one of SEQ ID NO 1 to SEQ ID NO 222. In another embodiment, an aptamer composition comprises at least one oligonucleotide having at least 40 contiguous nucleotides from at least one of SEQ ID NO 1 to SEQ ID NO 222. In another embodiment, an aptamer composition comprises at least one oligonucleotide having at least 60 contiguous nucleotides from at least one of SEQ ID NO 1 to SEQ ID NO 222. In another embodiment, an aptamer composition comprises at least one oligonucleotide having at least 70 contiguous nucleotides from at least one of SEQ ID NO 1 to SEQ ID NO 222. In another embodiment, an aptamer composition comprises at least one oligonucleotide having at least 80 contiguous nucleotides from at least one of SEQ ID NO 1 to SEQ ID NO 222.
In another embodiment, an aptamer composition comprises at least one oligonucleotide comprising SEQ ID NO 1, SEQ ID NO 9, SEQ ID NO 25, SEQ ID NO 112, SEQ ID NO 120, SEQ ID NO 136, or SEQ ID NO 223 to SEQ ID NO 234. In another embodiment, an aptamer composition comprises at least one oligonucleotide having at least 50% nucleotide sequence identity to at least one of SEQ ID NO 1, SEQ ID NO 9, SEQ ID NO 25, SEQ ID NO 112, SEQ ID NO 120, SEQ ID NO 136, or SEQ ID NO 223 to SEQ ID NO 234. In another embodiment, an aptamer composition comprises at least one oligonucleotide having at least 70% nucleotide sequence identity to at least one of SEQ ID NO 1, SEQ ID NO 9, SEQ ID NO 25, SEQ ID NO 112, SEQ ID NO 120, SEQ ID NO 136, or SEQ ID NO 223 to SEQ ID NO 234. In another embodiment, an aptamer composition comprises at least one oligonucleotide having at least 90% nucleotide sequence identity to at least one of SEQ ID NO 1, SEQ ID NO 9, SEQ ID NO 25, SEQ ID NO 112, SEQ ID NO 120, SEQ ID NO 136, or SEQ ID NO 223 to SEQ ID NO 234. Non-limiting examples of oligonucleotides with at least 90% nucleotide sequence identity to SEQ ID NO 1 are SEQ ID NO 49, SEQ ID NO 69, and SEQ ID NO 75. A non-limiting example of an oligonucleotide with at least 50% nucleotide sequence identity to SEQ ID NO 9 is SEQ ID NO 14.
In another embodiment, an oligonucleotide comprises at least one or more motifs of SEQ ID NO 235, SEQ ID NO 236, SEQ ID NO 237, SEQ ID NO 238, SEQ ID NO 239, SEQ ID NO 240, SEQ ID NO 241, SEQ ID NO 242, SEQ ID NO 243, or SEQ ID NO 244. In another embodiment, an aptamer composition comprises at least one oligonucleotide having at least 70% nucleotide sequence identity to at least one of SEQ ID NO 235, SEQ ID NO 236, SEQ ID NO 237, SEQ ID NO 238, SEQ ID NO 239, SEQ ID NO 240, SEQ ID NO 241, SEQ ID NO 242, SEQ ID NO 243, or SEQ ID NO 244. In another embodiment, an aptamer composition comprises at least one oligonucleotide having at least 80% nucleotide sequence identity to at least one of SEQ ID NO 235, SEQ ID NO 236, SEQ ID NO 237, SEQ ID NO 238, SEQ ID NO 239, SEQ ID NO 240, SEQ ID NO 241, SEQ ID NO 242, SEQ ID NO 243, or SEQ ID NO 244. In another embodiment, an aptamer composition comprises at least one oligonucleotide having at least 90% nucleotide sequence identity to at least one of SEQ ID NO 235, SEQ ID NO 236, SEQ ID NO 237, SEQ ID NO 238, SEQ ID NO 239, SEQ ID NO 240, SEQ ID NO 241, SEQ ID NO 242, SEQ ID NO 243, or SEQ ID NO 244.
In another embodiment, the fluorinated pyrimidine nucleotides of SEQ ID NO 1 to SEQ ID NO 111 and SEQ ID NO 223 to 228 are substituted by the corresponding natural non-fluorinated pyrimidine nucleotides.
Chemical modifications can introduce new features into the aptamers such as different molecular interactions with the target, improved binding capabilities, enhanced stability of oligonucleotide conformations, or increased resistance to nucleases. In certain embodiments, an oligonucleotide of an aptamer composition comprises natural or non-natural nucleobases. Natural nucleobases are adenine, cytosine, guanine, thymine, and uracil. Non-limiting examples of non-natural nucleobases are hypoxanthine, xanthine, 7-methylguanine, 5,6-dihydrouracil, 5-5-methylcytosine, 5-hydroxymethylcytosine, thiouracil, 1-methylhypoxanthine, 6-methylisoquinoline-1-thione-2-yl, 3-methoxy-2-naphthyl, 5-propynyluracil-1-yl, 5-methylcytosin-1-yl, 2-aminoadenin-9-yl, 7-deaza-7-iodoadenin-9-yl, 7-deaza-7-propynyl-2-aminoadenin-9-yl, phenoxazinyl, phenoxazinyl-G-clam, bromouracil, 5-iodouracil, and mixtures thereof.
Modifications of the phosphate backbone of the oligonucleotides can also increase the resistance against nuclease digestion. In certain embodiments, the nucleosides of oligonucleotides are linked by a chemical motif that is at least one of: natural phosphate diester, chiral phosphorothionate, chiral methyl phosphonate, chiral phosphoramidate, chiral phosphate chiral triester, chiral boranophosphate, chiral phosphoroselenoate, phosphorodithioate, phosphorothionate amidate, methylenemethylimino, 3′-amide, 3′ achiral phosphoramidate, 3′ achiral methylene phosphonates, thioformacetal, thioethyl ether, fluorophosphate, or mixtures thereof. In another embodiment, the nucleosides of oligonucleotides may be linked by natural phosphate diesters.
In another embodiment, the sugar moiety of the nucleosides of oligonucleotides may be at least one of: ribose, deoxyribose, 2′-fluoro deoxyribose, 2′-O-methyl ribose, 2′-O-(3-amino)propyl ribose, 2′-O-(2-methoxy)ethyl ribose, 2′-O-2-(N,N-dimethylaminooxy)ethyl ribose, 2′-O-2-[2-(N,N-dimethylamino)ethyloxy]ethyl ribose, 2′-O—N,N-dimethylacetamidyl ribose, N-morpholinophosphordiamidate, α-deoxyribofuranosyl, other pentoses, hexoses, or mixtures thereof.
In another embodiment, said derivatives of ribonucleotides or derivatives of deoxyribonucleotides may be at least one of: locked oligonucleotides, peptide oligonucleotides, glycol oligonucleotides, threose oligonucleotides, hexitol oligonucleotides, altritol oligonucleotides, butyl oligonucleotides, L-ribonucleotides, arabino oligonucleotides, 2′-fluoroarabino oligonucleotides, cyclohexene oligonucleotides, phosphorodiamidate morpholino oligonucleotides, or mixtures thereof.
In another embodiment, the nucleotides at the 5′- and 3′-ends of an oligonucleotide are inverted. In another embodiment, at least one nucleotide of an oligonucleotide is fluorinated at the 2′ position of the pentose group. In another embodiment, the pyrimidine nucleotides of an oligonucleotide are fluorinated at the 2′ position of the pentose group. In another embodiment, the aptamer composition further comprises at least one polymeric material, wherein the polymeric material may be covalently linked to an oligonucleotide; wherein the polymeric material may be polyethylene glycol.
In another embodiment, an oligonucleotide may be between about 10 and about 200 nucleotides in length. In another embodiment, an oligonucleotide may be less than about 100 nucleotides in length. In yet another embodiment, an oligonucleotide may be less than about 50 nucleotides in length.
In another embodiment, an oligonucleotide may be covalently or non-covalently attached to one or more oral care active ingredients. Suitable oral care active ingredients include any material that is generally considered as safe for use in the oral cavity and that provides changes to the overall health of the oral cavity; and specifically, to the condition of the oral surfaces that such oral care active ingredients interact with. Examples of oral conditions these actives address include, but are not limited to, appearance and structural changes to teeth, whitening, stain prevention and removal, stain bleaching, plaque prevention and removal, tartar prevention and removal, cavity prevention and treatment, inflamed and/or bleeding gums, mucosal wounds, lesions, ulcers, aphthous ulcers, cold sores, and tooth abscesses.
In another embodiment, said one or more oral care active ingredients are selected from the group comprising: whitening agents, brightening agents, anti-stain agents, anti-cavity agents, anti-erosion agents, anti-tartar agents, anti-calculus agents, anti-plaque agents, teeth remineralizing agents, anti-fracture agents, strengthening agents, abrasion resistance agents, anti-gingivitis agents, anti-microbial agents, anti-bacterial agents, anti-fungal agents, anti-yeast agents, anti-viral, anti-malodor agents, breath freshening agents, flavoring agents, cooling agents, taste enhancement agents, olfactory enhancement agents, anti-adherence agents, smoothness agents, surface modification agents, anti-tooth pain agents, anti-sensitivity agents, anti-inflammatory agents, gum protecting agents, periodontal actives, tissue regeneration agents, anti-blood coagulation agents, anti-clot stabilizer agents, salivary stimulant agents, salivary rheology modification agents, enhanced retention agents, soft/hard tissue targeted agents, tooth/soft tissue cleaning agents, antioxidants, pH modifying agents, H-2 antagonists, analgesics, natural extracts and essential oils, dyes, optical brighteners, cations, phosphates, fluoride ion sources, peptides, nutrients, enzymes, mouth and throat products, and mixtures thereof. Non-limiting specific examples of oral care active ingredients are listed in Section IV.
In another embodiment, an oligonucleotide is non-covalently attached to one or more oral care active ingredients, via molecular interactions. Examples of molecular interactions are electrostatic forces, van der Waals interactions, hydrogen bonding, and π-π stacking interactions of aromatic rings.
In another embodiment, an oligonucleotide may be covalently attached to said one or more oral care active ingredients using one or more linkers or spacers. Non-limiting examples of linkers are chemically labile linkers, enzyme-labile linkers, and non-cleavable linkers. Examples of chemically labile linkers are acid-cleavable linkers and disulfide linkers. Acid-cleavable linkers take advantage of low pH to trigger hydrolysis of an acid-cleavable bond, such as a hydrazone bond, to release the active ingredient or payload. Disulfide linkers can release the active ingredients under reducing environments. Examples of enzyme-labile linkers are peptide linkers that can be cleaved in the present of proteases and β-glucuronide linkers that are cleaved by glucuronidases releasing the payload. Non-cleavable linkers can also release the active ingredient if the aptamer is degraded by nucleases.
In another embodiment, an oligonucleotide may be covalently or non-covalently attached to one or more nanomaterials. In another embodiment, an oligonucleotide and one or more oral care active ingredients may be covalently or non-covalently attached to one or more nanomaterials. In another embodiment, one or more oral care active ingredients are carried by one or more nanomaterials. Non-limiting examples of nanomaterials are gold nanoparticles, nano-scale iron oxides, carbon nanomaterials (such as single-walled carbon nanotubes and graphene oxide), mesoporous silica nanoparticles, quantum dots, liposomes, poly (lactide-co-glycolic acids) nanoparticles, polymeric micelles, dendrimers, serum albumin nanoparticles, and DNA-based nanomaterials. These nanomaterials can serve as carriers for large volumes of oral care active ingredients, while the aptamers can facilitate the delivery of the nanomaterials with the actives to the expected target.
Nanomaterials can have a variety of shapes or morphologies. Non-limiting examples of shapes or morphologies are spheres, rectangles, polygons, disks, toroids, cones, pyramids, rods/cylinders, and fibers. In the context of the present invention, nanomaterials may have at least one spatial dimension that is less than about 100 μm and more preferably less than about 10 μm. Nanomaterials comprise materials in solid phase, semi-solid phase, or liquid phase.
Aptamers can also be peptides that bind to targets with high affinity and specificity. These peptide aptamers can be part of a scaffold protein. Peptide aptamers can be isolated from combinatorial libraries and improved by directed mutation or rounds of variable region mutagenesis and selection. In certain embodiments of the present invention, an aptamer composition may comprise at least one peptide or protein; wherein the aptamer composition has a binding affinity for a material selected from the group consisting of: tooth, enamel, dentin, hydroxyapatite, carbonated calcium-deficient hydroxyapatite, and mixtures thereof.

Methods of Designing Aptamer Compositions

The method of designing nucleic acid aptamers known as Systematic Evolution of Ligands by Exponential Enrichment (SELEX) has been broadly studied and improved for the selection of aptamers against small molecules and proteins (WO 91/19813). In brief, in the conventional version of SELEX, the process starts with the synthesis of a large library of oligonucleotides consisting of randomly generated sequences of fixed length flanked by constant 5′- and 3′-ends that serve as primers. The oligonucleotides in the library are then exposed to the target ligand and those that do not bind the target are removed. The bound sequences are eluted and amplified by PCR to prepare for subsequent rounds of selection in which the stringency of the elution conditions is usually increased to identify the tightest-binding oligonucleotides. In addition to conventional SELEX, there are improved versions such as capillary electrophoresis-SELEX, magnetic bead-based SELEX, cell-SELEX, automated SELEX, complex-target SELEX, among others. A review of aptamer screening methods is found in “Kim, Y. S. and M. B. Gu (2014). Advances in Aptamer Screening and Small Molecule Aptasensors. Adv. Biochem. Eng./Biotechnol. 140 (Biosensors based on Aptamers and Enzymes): 29-67” and “Stoltenburg, R., et al. (2007). SELEX-A (r)evolutionary method to generate high-affinity nucleic acid ligands. Biomol. Eng. 24(4): 381-403,” the contents of which are incorporated herein by reference. Although the SELEX method has been broadly applied, it is neither predictive nor standardized for every target. Instead, a method must be developed for each particular target in order for the method to lead to viable aptamers.
Despite the large number of selected aptamers, SELEX has not been routinely applied for the selection of aptamers with binding affinities towards macroscopic materials and surfaces. For the successful selection of aptamers with high binding affinity and specificity against macroscopic materials, the epitope should be present in sufficient amount and purity to minimize the enrichment of unspecifically binding oligonucleotides and to increase the specificity of the selection. Also, the presence of positively charged groups (e.g. primary amino groups), the presence of hydrogen bond donors and acceptors, and planarity (aromatic compounds) facilitate the selection of aptamers. In contrast, negatively charged molecules (e.g. containing phosphate groups) make the selection process more difficult. Unexpectedly, in spite of the detrimental chemical features of teeth that make aptamer selection challenging, the inventors have found that SELEX can be used for the design of aptamers with high binding affinity and specificity for teeth.

Selection Library

In SELEX, the initial candidate library is generally a mixture of chemically synthesized DNA oligonucleotides, each comprising a long variable region of n nucleotides flanked, at the 3′ and 5′ ends, by conserved regions or primer recognition regions for all the candidates of the library. These primer recognition regions allow the central variable region to be manipulated during SELEX, in particular by means of PCR.
The length of the variable region determines the diversity of the library, which is equal to 4ⁿsince each position can be occupied by one of four nucleotides A, T, G or C. For long variable regions, huge library complexities arise. For instance, when n=50, the theoretical diversity is 4⁵⁰or 10³⁰, which is an inaccessible value in practice as it corresponds to more than 10⁵tons of material for a library wherein each sequence is represented once. The experimental limit is around 10¹⁵different sequences, which is that of a library wherein all candidates having a variable region of 25 nucleotides are represented. If one chooses to manipulate a library comprising a 30-nucleotide variable region whose theoretical diversity is about 10¹⁸, only 1/1000 of the possibilities will thus be explored. In practice, that is generally sufficient to obtain aptamers having the desired properties. Additionally, since the polymerases used are unreliable and introduce errors at a rate on the order of 10⁻⁴, they contribute to significantly enrich the diversity of the sequence pool throughout the SELEX process: one candidate in 100 will be modified in each amplification cycle for a library with a random region of 100 nucleotides in length, thus leading to the appearance of 10¹³new candidates for the overall library.
In certain embodiments of the present invention, the starting mixture of oligonucleotides may comprise more than about 10⁶different oligonucleotides or from between about 10¹³to about 10¹⁵different oligonucleotides. In another embodiment of the present invention, the length of the variable region may be between about 10 and about 100 nucleotides. In another embodiment, the length of the variable region may be between about 20 and about 60 nucleotides. In yet another embodiment, the length of the variable region is about 40 nucleotides. Random regions shorter than 10 nucleotides may be used, but may be constrained in their ability to form secondary or tertiary structures and in their ability to bind to target molecules. Random regions longer than 100 nucleotides may also be used but may present difficulties in terms of cost of synthesis. The randomness of the variable region is not a constraint of the present invention. For instance, if previous knowledge exists regarding oligonucleotides that bind to a given target, libraries spiked with such sequences may work as well or better than completely random ones.
In the design of primer recognition sequences care should be taken to minimize potential annealing among sequences, fold back regions within sequences, or annealing of the same sequence itself. In certain embodiments of the present invention, the length of primer recognition sequences may be between about 10 and about 40 nucleotides. In another embodiment, the length of primer recognition sequences may be between about 12 and about 30 nucleotides. In yet another embodiment, the length of primer recognition sequences may be between about 18 and about 26 nucleotides, i.e., about 18, 19, 20, 21, 22, 23, 24, 25 or 26 nucleotides. The length and sequence of the primer recognition sequences determine their annealing temperature. In certain embodiments, the primer recognition sequences of oligonucleotides may have an annealing temperature between about 60° C. and about 72° C.
Aptamers can be ribonucleotides (RNA), deoxynucleotides (DNA), or their derivatives. When aptamers are ribonucleotides, the first SELEX step may consist in transcribing the initial mixture of chemically synthesized DNA oligonucleotides via the primer recognition sequence at the 5′ end. After selection, the candidates are converted back into DNA by reverse transcription before being amplified. RNA and DNA aptamers having comparable characteristics have been selected against the same target and reported in the art. Additionally, both types of aptamers can be competitive inhibitors of one another, suggesting potential overlapping of interaction sites.
New functionalities, such as hydrophobicity or photoreactivity, can be incorporated into the oligonucleotides by modifications of the nucleobases before or after selection. Modifications at the C-5 position of pyrimidines or at the C-8 or N-7 positions of purines are especially common and compatible with certain enzymes used during the amplification step in SELEX. In certain embodiments of the present invention, said oligonucleotides comprise natural or non-natural nucleobases. Natural nucleobases are adenine, cytosine, guanine, thymine, and uracil. Non-limiting examples of non-natural nucleobases are hypoxanthine, xanthine, 7-methylguanine, 5,6-dihydrouracil, 5-5-methylcytosine, 5-hydroxymethylcytosine, thiouracil, 1-methylhypoxanthine, 6-methylisoquinoline-1-thione-2-yl, 3-methoxy-2-naphthyl, 5-propynyluracil-1-yl, 5-methylcytosin-1-yl, 2-aminoadenin-9-yl, 7-deaza-7-iodoadenin-9-yl, 7-deaza-7-propynyl-2-aminoadenin-9-yl, phenoxazinyl, phenoxazinyl-G-clam, 5-bromouracil, 5-iodouracil, and mixtures thereof. Some non-natural nucleobases, such as 5-bromouracil or 5-iodouracil, can be used to generate photo-cross-linkable aptamers, which can be activated by UV light to form a covalent link with the target.
In another embodiment, the nucleosides of said oligonucleotides are linked by a chemical motif selected from the group comprising: natural phosphate diester, chiral phosphorothionate, chiral methyl phosphonate, chiral phosphoramidate, chiral phosphate chiral triester, chiral boranophosphate, chiral phosphoroselenoate, phosphorodithioate, phosphorothionate amidate, methylenemethylimino, 3′-amide, 3′ achiral phosphoramidate, 3′ achiral methylene phosphonates, thioformacetal, thioethyl ether, fluorophosphate, and mixtures thereof. In yet another embodiment, the nucleosides of said oligonucleotides are linked by natural phosphate diesters.
In another embodiment, the sugar moiety of the nucleosides of said oligonucleotides may be selected from the group comprising: ribose, deoxyribose, 2′-fluoro deoxyribose, 2′-O-methyl ribose, 2′-O-(3-amino)propyl ribose, 2′-O-(2-methoxy)ethyl ribose, 2′-O-2-(N,N-dimethylaminooxy)ethyl ribose, 2′-O-2-[2-(N,N-dimethylamino)ethyloxy]ethyl ribose, 2′-O—N,N-dimethylacetamidyl ribose, N-morpholinophosphordiamidate, α-deoxyribofuranosyl, other pentoses, hexoses, and mixtures thereof.
In another embodiment, said derivatives of ribonucleotides or said derivatives of deoxyribonucleotides are selected from the group comprising: locked oligonucleotides, peptide oligonucleotides, glycol oligonucleotides, threose oligonucleotides, hexitol oligonucleotides, altritol oligonucleotides, butyl oligonucleotides, L-ribonucleotides, arabino oligonucleotides, 2′-fluoroarabino oligonucleotides, cyclohexene oligonucleotides, phosphorodiamidate morpholino oligonucleotides, and mixtures thereof.
When using modified nucleotides during the SELEX process, they should be compatible with the enzymes used during the amplification step. Non-limiting examples of modifications that are compatible with commercial enzymes include modifications at the 2′ position of the sugar in RNA libraries. The ribose 2′-OH group of pyrimidine nucleotides can be replaced with 2′-amino, 2′-fluoro, 2′-methyl, or 2′-O-methyl, which protect the RNA from degradation by nucleases. Additional modifications in the phosphate linker, such as phosphorothionate and boranophosphate, are also compatible with the polymerases and confer resistance to nucleases.
In certain embodiments of the present invention, at least one nucleotide of said oligonucleotides is fluorinated at the 2′ position of the pentose group. In another embodiment, the pyrimidine nucleotides of said oligonucleotides are at least partially fluorinated at the 2′ position of the pentose group. In yet another embodiment, all the pyrimidine nucleotides of said oligonucleotides are fluorinated at the 2′ position of the pentose group. In another embodiment, at least one nucleotide of said oligonucleotides is aminated at the 2′ position of the pentose group.
Another approach, recently described as two-dimensional SELEX, simultaneously applies in vitro oligonucleotide selection and dynamic combinatorial chemistry (DCC), e.g., a reversible reaction between certain groups of the oligonucleotide (amine groups) and a library of aldehyde compounds. The reaction produces imine oligonucleotides which are selected on the same principles as for conventional SELEX. It was thus possible to identify for a target hairpin RNA modified aptamers that differ from natural aptamers.
A very different approach relates to the use of optical isomers. Natural oligonucleotides are D-isomers. L-analogs are resistant to nucleases but cannot be synthesized by polymerases. According to the laws of optical isomerism, an L-series aptamer can form with its target (T) a complex having the same characteristics as the complex formed by the D-series isomer and the enantiomer (T′) of the target (T). Consequently, if compound T′ can be chemically synthesized, it can be used to perform the selection of a natural aptamer (D). Once identified, this aptamer can be chemically synthesized in an L-series. This L-aptamer is a ligand of the natural target (T).

Selection Step

Single stranded oligonucleotides can fold to generate secondary and tertiary structures, resembling the formation of base pairs. The initial sequence library is thus a library of three-dimensional shapes, each corresponding to a distribution of units that can trigger electrostatic interactions, create hydrogen bonds, etc. Selection becomes a question of identifying in the library the shape suited to the target, i.e., the shape allowing the greatest number of interactions and the formation of the most stable aptamer-target complex. For small targets (dyes, antibiotics, etc.) the aptamers identified are characterized by equilibrium dissociation constants in the micromolar range, whereas for protein targets K_dvalues below 10⁻⁹M are not rare.
Selection in each round occurs by means of physical separation of oligonucleotides associated with the target from free oligonucleotides. Multiple techniques may be applied (chromatography, filter retention, electrophoresis, etc.). The selection conditions are adjusted (relative concentration of target/candidates, ion concentration, temperature, washing, etc.) so that a target-binding competition occurs between the oligonucleotides. Generally, stringency is increased as the rounds proceed in order to promote the capture of oligonucleotides with the highest affinity. In addition, counter-selections or negative selections are carried out to eliminate oligonucleotides that recognize the support or unwanted targets (e.g., filter, beads, etc.).
The SELEX process for the selection of target-specific aptamers is characterized by repetition of five main steps: binding of oligonucleotides to the target, partition or removal of oligonucleotides with low binding affinity, elution of oligonucleotides with high binding affinity, amplification or replication of oligonucleotides with high binding affinity, and conditioning or preparation of the oligonucleotides for the next cycle. This selection process is designed to identify the oligonucleotides with the greatest affinity and specificity for the target material.
In certain embodiments of the present invention, a method of designing an aptamer composition comprises the step of contacting: a) a mixture of oligonucleotides, b) a selection buffer, and c) a target material selected from the group consisting of: tooth, enamel, dentin, hydroxyapatite, carbonated calcium-deficient hydroxyapatite, and mixtures thereof. In another embodiment, said target material is tooth. In another embodiment, said tooth is at least partially coated with saliva before said contacting step. In another embodiment of the present invention, said mixture of oligonucleotides comprises oligonucleotides selected from the group consisting of deoxyribonucleotides, ribonucleotides, derivatives of deoxyribonucleotides, derivatives of ribonucleotides, and mixtures thereof.
SELEX cycles are usually repeated several times until oligonucleotides with high binding affinity are identified. The number of cycles depends on multiple variables, including target features and concentration, design of the starting random oligonucleotide library, selection conditions, ratio of target binding sites to oligonucleotides, and the efficiency of the partitioning step. In certain embodiments, said contacting step is performed at least 5 times. In another embodiment, said contacting step is performed between 6 and 15 times. In another embodiment, said method further comprises the step of removing the oligonucleotides that do not bind said target material during said contacting step.
Oligonucleotides are oligo-anions, each unit having a charge and hydrogen-bond donor/acceptor sites at a particular pH. Thus, the pH and ionic strength of the selection buffer are important and should represent the conditions of the intended aptamer application. In certain embodiments of the present invention, the pH of said selection buffer is between about 2 and about 9. In another embodiment, the pH of said selection buffer is between about 6 and about 8. In yet another embodiment, the pH of said selection buffer is between about 2 and about 5. Selection buffers with low pH can be important if the aptamers are expected to have good binding affinities in acidic environments.
Cations can facilitate the proper folding of the oligonucleotides and provide benefits in the oral cavity. In certain embodiments of the present invention, said selection buffer comprises cations. Non-limiting examples of cations are Ca²⁺, Sn²⁺, Sn⁴⁺, Zn²⁺, Al³⁺, Cu²⁺, Fe²⁺, and Fe³⁺. In yet another embodiment, said selection buffer comprises divalent cations selected from the group comprising Sn²⁺ and Ca²⁺.
In order for the aptamers to maintain their structures and function during their application, the in vitro selection process can be carried out under conditions similar to those for which they are being developed. In certain embodiments of the present invention, said selection buffer comprises a solution or suspension of an oral care composition selected from the group comprising dentifrices, dentifrices, toothpowders, mouthwashes, mouthrinses, flosses, brushes, strips, sprays, patches, paint on, dissolvables, edibles, lozenges, gums, chewables, soluble fibers, insoluble fibers, putties, waxes, denture adhesives, denture cleansers, and mixtures thereof. In another embodiment of the present invention, said selection buffer comprises a solution of a dentifrice. In another embodiment of the present invention, said selection buffer comprises a solution of saliva.
In certain embodiments of the present invention, said selection buffer comprises at least one surfactant. In another embodiment, said at least one surfactant is selected from the group comprising sodium lauryl sulfate, betaines, chlorhexidine, sarcosinates, pluronics and triclosan. In another embodiment, said at least one surfactant is sodium lauryl sulfate. In another embodiment, said selection buffer comprises at least one abrasive material selected from the group comprising aluminum hydroxide, calcium carbonate, calcium hydrogen phosphates, calcium pyrophosphate, calcium pyrophosphate (beta phase), silicates, aluminosilicates, hydroxyapatite, and mixtures thereof. In yet another embodiment, said selection buffer comprises: a) at least one surfactant; b) at least one abrasive material selected from the group comprising aluminum hydroxide, calcium carbonate, calcium hydrogen phosphates, calcium pyrophosphate, calcium pyrophosphate (beta phase), silicates, aluminosilicates, hydroxyapatite, and mixtures thereof; c) at least one phosphate salt; and d) at least one fluoride salt.
Negative selection or counter-selection steps can minimize the enrichment of oligonucleotides that bind to undesired targets or undesired epitopes within a target. For oral care applications, binding of aptamers to teeth staining materials may not be desirable. In certain embodiments of the present invention, said method of designing an aptamer composition further comprises the step of contacting: a) a mixture of oligonucleotides, b) a selection buffer, and c) one or more teeth staining materials. In another embodiment, said one or more teeth staining materials comprise one or more natural or synthetic dyes or pigments selected from the group comprising flavonoids, carotenoids, caramels, tannins, other chromogens, and mixtures thereof. In yet another embodiment, said one or more teeth staining materials are selected from the group comprising wine, coffee, tea, carbonated sodas, and mixtures thereof. During the negative selection or counter-selection, the teeth staining materials can be either unbound or immobilized to a support. Methods for negative selection or counter-selection of aptamers against unbound targets have been published in WO201735666, the content of which is incorporated herein by reference.
In certain embodiments of the present invention, the method of designing an aptamer composition may comprise the steps of: a) synthesizing a mixture of oligonucleotides; b) contacting: i. said mixture of oligonucleotides, ii. a selection buffer, and iii. a target material selected from the group consisting of: tooth, enamel, dentin, hydroxyapatite, carbonated calcium-deficient hydroxyapatite, and mixtures thereof, to produce a target suspension; c) removing the liquid phase from said target suspension to produce a target-oligonucleotide mixture; d) contacting said target-oligonucleotide mixture with a washing buffer and removing the liquid phase to produce a target-aptamer mixture; and e) contacting said target-aptamer mixture with an elution buffer and recovering the liquid phase to produce an aptamer mixture. In another embodiment, said steps are performed repetitively at least 5 times. In another embodiment, said steps are performed between 6 and 15 times.
In another embodiment, a method of designing an aptamer composition comprising the steps of: a) synthesizing a random mixture of deoxyribonucleotides comprising oligonucleotides consisting of: i. a T7 promoter sequence at the 5′-end, ii. a variable 40-nucleotide sequence in the middle, and iii. a conserved reverse primer recognition sequence at the 3′ end; b) transcribing said random mixture of deoxyribonucleotides using pyrimidine nucleotides fluorinated at the 2′ position of the pentose group and natural purine nucleotides and a mutant T7 polymerase to produce a mixture of fluorinated ribonucleotides; c) contacting: i. said mixture of fluorinated ribonucleotides, ii. a selection buffer, and iii. a tooth, wherein said tooth is at least partially coated with saliva, to produce a target suspension; d) removing the liquid phase from said target suspension to produce a tooth-oligonucleotide mixture; e) contacting said tooth-oligonucleotide mixture with a washing buffer and removing the liquid phase to produce a tooth-aptamer mixture; f) contacting said tooth-aptamer mixture with an elution buffer and recovering the liquid phase to produce an RNA aptamer mixture; g) reserve transcribing and amplifying said RNA aptamer mixture to produce a DNA copy of said RNA aptamer mixture; and h) sequencing said DNA copy of said RNA aptamer mixture.

Post-Selection Modification

To enhance stability of the aptamers, chemical modifications can be introduced in the aptamer after the selection process. For instance, the 2′-OH groups of the ribose moieties can be replaced by 2′-fluoro, 2′-amino, or 2′-O-methyl groups. Furthermore, the 3′- and 5′-ends of the aptamers can be capped with different groups, such as streptavidin-biotin, inverted thymidine, amine, phosphate, polyethylene-glycol, cholesterol, fatty acids, proteins, enzymes, fluorophores, among others, making the oligonucleotides resistant to exonucleases or providing some additional benefits. Other modifications are described in previous sections of the present disclosure.
Unlike backbone modifications which can cause aptamer-target interaction properties to be lost, it is possible to conjugate various groups at one of the 3′- or 5′-ends of the oligonucleotide in order to convert it into a delivery vehicle, tool, probe, or sensor without disrupting its characteristics. This versatility constitutes a significant advantage of aptamers, in particular for their application in the current invention. In certain embodiments of the present invention, one or more oral care active ingredients are covalently attached to the 3′-end of an oligonucleotide. In another embodiment, one or more oral care active ingredients are covalently attached to the 5′-end of an oligonucleotide. In yet another embodiment, one or more oral care active ingredients are covalently attached to random positions of an oligonucleotide.
Incorporation of modifications to aptamers can be performed using enzymatic or chemical methods. Non-limiting examples of enzymes used for modification of aptamers are terminal deoxynucleotidyl transferases (TdT), T4 RNA ligases, T4 polynucleotide kinases (PNK), DNA polymerases, RNA polymerases, and other enzymes known by those skilled in the art. TdTs are template-independent polymerases that can add modified deoxynucleotides to the 3′ terminus of deoxyribonucleotides. T4 RNA ligases can be used to label ribonucleotides at the 3′-end by using appropriately modified nucleoside 3′,5′-bisphosphates. PNK can be used to phosphorylate the 5′-end of synthetic oligonucleotides, enabling other chemical transformations (see below). DNA and RNA polymerases are commonly used for the random incorporation of modified nucleotides throughout the sequence, provided such nucleotides are compatible with the enzymes.
Non-limiting examples of chemical methods used for modification of aptamers are periodate oxidation of ribonucleotides, EDC activation of 5′-phosphate, random chemical labeling methods, and other chemical methods known by those skilled in the art, incorporated herein as embodiments of the current invention.
During periodate oxidation, meta- and ortho-perdionates cleave the C—C bonds between vicinal diols of 3′-ribonucleotides, creating two aldehyde moieties that enable the conjugation of labels or active ingredients at the 3′-end of RNA aptamers. The resulting aldehydes can be easily reacted with hydrazide- or primary amine-containing molecules. When amines are used, the produced Schiff bases can be reduced to more stable secondary amines with sodium cyanoborohydride (NaBH₄).
When EDC activation of 5′-phosphate is used, the 5′-phosphate of oligonucleotides is frequently activated with EDC (1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride) and imidazole to produce a reactive imidazolide intermediate, followed by reaction with a primary amine to generate aptamers modified at the 5′end. Because the 5′ phosphate group is required for the reaction, synthetic oligonucleotides can be first treated with a kinase (e.g. PNK).
Random chemical labeling can be performed with different methods. Because they allow labeling at random sites along the aptamer, a higher degree of modification can be achieved compared to end-labeling methods. However, since the nucleobases are modified, binding of the aptamers to their target can be disrupted. The most common random chemical modification methods involve the use of photoreactive reagents, such as phenylazide-based reagents. When the phenylazide group is exposed to UV light, it forms a labile nitrene that reacts with double bonds and C—H and N—H sites of the aptamers.
Additional information about methods for modification of aptamers is summarized in “Hermanson G. T. (2008). Bioconjugate Techniques. 2nd Edition. pp. 969-1002, Academic Press, San Diego.”, the content of which is incorporated herein by reference.
After selection, in addition to chemical modifications, sequence truncations can be performed to remove regions that are not essential for binding or for folding into the structure. Moreover, aptamers can be linked together to provide different features or better affinity. Thus, any truncations or combinations of the aptamers described herein are incorporated as part of the current invention.

Application of Aptamer Compositions in Oral Care Products

The aptamers of the current invention can be used in oral care compositions to provide one or more benefits. In certain embodiments of the present invention, an oral care composition comprises at least one nucleic acid aptamer; wherein said at least one nucleic acid aptamer has a binding affinity for an oral cavity component. In another embodiment, an oral care composition comprises at least one nucleic acid aptamer; wherein said at least one nucleic acid aptamer has a binding affinity for an oral cavity component selected from the group comprising: tooth, enamel, dentin, and any other surfaces in the oral cavity. In another embodiment, an oral care composition comprises at least one nucleic acid aptamer; wherein said at least one nucleic acid aptamer has a binding affinity for tooth.
The oral care compositions of the present invention can be in different forms. Non-limiting examples of said forms are: dentifrices (including dentifrices and toothpowders), mouthwashes, mouthrinses, flosses, brushes, strips, sprays, patches, paint on, dissolvables, edibles, lozenges, gums, chewables, soluble fibers, insoluble fibers, putties, waxes, denture adhesives, denture cleansers, liquids, pastes, Newtonian or non-Newtonian fluids, gels, and sols.
The oral acre compositions of the present invention may include one or more of the following:
Rheology modifiers suitable for use in the present invention include organic and inorganic rheology modifiers, and mixtures thereof. Inorganic rheology modifiers include hectorite and derivatives, hydrated silicas, ternary and quaternary magnesium silicate derivatives, bentonite and mixtures thereof. Preferred inorganic rheology modifiers are hectorite and derivatives, hydrated silicas and mixtures thereof. Organic rheology modifiers include xanthan gum, carrageenan and derivatives, gellan gum, hydroxypropyl methyl cellulose, sclerotium gum and derivatives, pullulan, rhamsan gum, welan gum, konjac, curdlan, carbomer, algin, alginic acid, alginates and derivatives, hydroxyethyl cellulose and derivatives, hydroxypropyl cellulose and derivatives, starch phosphate derivatives, guar gum and derivatives, starch and derivatives, co-polymers of maleic acid anhydride with alkenes and derivatives, cellulose gum and derivatives, ethylene glycol/propylene glycol co-polymers, poloxamers and derivatives, polyacrylates and derivatives, methyl cellulose and derivatives, ethyl cellulose and derivatives, agar and derivatives, gum arabic and derivatives, pectin and derivatives, chitosan and derivatives, resinous polyethylene glycols such as PEG-XM where X is >=1, karaya gum, locust bean gum, natto gum, co-polymers of vinyl pyrollidone with alkenes, tragacanth gum, polyacrylamides, chitin derivatives, gelatin, betaglucan, dextrin, dextran, cyclodextrin, methacrylates, microcrystalline cellulose, polyquatemiums, furcellaren gum, ghatti gum, psyllium gum, quince gum, tamarind gum, larch gum, tara gum, and mixtures thereof. Preferred are xanthan gum, carrageenan and derivatives, gellan gum, hydroxypropyl methyl cellulose, sclerotium gum and derivatives, pullulan, rhamsan gum, welan gum, konjac, curdlan, carbomer, algin, alginic acid, alginates and derivatives, hydroxyethyl cellulose and derivatives, hydroxypropyl cellulose and derivatives, starch phosphate derivatives, guar gum and derivatives, starch and derivatives, co-polymers of maleic acid anhydride with alkenes and derivatives, cellulose gum and derivatives, ethylene glycol/propylene glycol co-polymers, poloxamers and derivatives and mixtures thereof.
In certain embodiments amounts of rheology modifiers may range from about 0.1% to about 15% or from about 0.5% to about 3% by weight of the total composition, such as dentifrice.
In addition to the above components, a sweetener, a flavor, a preservative, an effective ingredient, abrasives, fluoride ion sources, chelating agents, antimicrobials, silicone oils and other adjuvants such as preservatives and coloring agents, etc. may be added as required.
As the sweetener, saccharin sodium, sucrose, maltose, lactose, stevioside, neohesperidildigydrochalcone, glycyrrhizin, perillartine, p-methoxycinnamic aldehyde and the like may be used, in an amount of 0.05 to 5% by weight of the total composition. Essential oils such as spearmint oil, peppermint oil, salvia oil, eucalptus oil, lemon oil, lime oil, wintergreen oil and cinnamon oil, other spices and fruit flavors as well as isolated and synthetic flavoring materials such as 1-menthol, carvone, anethole, eugenol and the like can be used as flavors. The flavor may be blended in an amount of 0.1 to 5% by weight of the total composition. Ethyl paraoxy benzonate, butyl paraoxy benzoate, etc. may be used as the preservative. The sweetener may be added with the abrasive. The flavor and the preservative may be added when preparing the liquid of the slightly swollen rheology modifier or mixed with rheology modifier after mixing with the humectant. Enzymes such as dextranase, lytic enzyme, lysozyme, amylase and antiplasmin agents such as EPSILON-aminocaproic acid and tranexamic acid, fluorine compounds such as sodium monofluorophosphate sodium fluoride and stannous fluoride, chlorhexidine salts, quaternary ammonium salts, aluminum chlorohydroxyl allantoin, glycyrrhetinic acid, chlorophyll, sodium chloride and phosphoric compounds may be used as the effective ingredient. Moreover, silica gel, aluminum silica gel, organic acids and their salts may be blended as desired. An organic effective ingredient with low viscosity may be added when preparing the liquid of the slightly swollen rheology modifier.
The oral care compositions of the present invention may comprise greater than about 0.1% by weight of a surfactant or mixture of surfactants. Surfactant levels cited herein are on a 100% active basis, even though common raw materials such as sodium lauryl sulphate may be supplied as aqueous solutions of lower activity.
Suitable surfactant levels are from about 0.1% to about 15%, from about 0.25% to about 10%, or from about 0.5% to about 5% by weight of the total composition. Suitable surfactants for use herein include anionic, amphoteric, non-ionic, zwitterionic and cationic surfactants, though anionic, amphoteric, non-ionic and zwitterionic surfactants (and mixtures thereof) are preferred.
Useful anionic surfactants herein include the water-soluble salts of alkyl sulphates and alkyl ether sulphates having from 10 to 18 carbon atoms in the alkyl radical and the water-soluble salts of sulphonated monoglycerides of fatty acids having from 10 to 18 carbon atoms. Sodium lauryl sulphate and sodium coconut monoglyceride sulphonates are examples of anionic surfactants o this type.
Suitable cationic surfactants useful in the present invention can be broadly defined as derivatives of aliphatic quaternary ammonium compounds having one long alkyl chain containing from about 8 to 18 carbon atoms such as lauryl trimethylammonium chloride; cetyl pyridinium chloride; benzalkonium chloride; cetyl trimethylammonium bromide; di-isobutylphenoxyethyl-dimethylbenzylammonium chloride; coconut alkyltrimethyl-ammonium nitrite; cetyl pyridinium fluoride; etc. Certain cationic surfactants can also act as germicides in the compositions disclosed herein.
Suitable nonionic surfactants that can be used in the compositions of the present invention can be broadly defined as compounds produced by the condensation of alkylene oxide groups (hydrophilic in nature) with an organic hydrophobic compound which may be aliphatic and/or aromatic in nature. Examples of suitable nonionic surfactants include the poloxamers; sorbitan derivatives, such as sorbitan di-isostearate; ethylene oxide condensates of hydrogenated castor oil, such as PEG-30 hydrogenated castor oil; ethylene oxide condensates of aliphatic alcohols or alkyl phenols; products derived from the condensation of ethylene oxide with the reaction product of propylene oxide and ethylene diamine; long chain tertiary amine oxides; long chain tertiary phosphine oxides; long chain dialkyl sulphoxides and mixtures of such materials. These materials are useful for stabilising foams without contributing to excess viscosity build for the oral care composition.
Zwitterionic surfactants can be broadly described as derivatives of aliphatic quaternary ammonium, phosphonium, and sulphonium compounds, in which the aliphatic radicals can be straight chain or branched, and wherein one of the aliphatic substituents contains from about 8 to 18 carbon atoms and one contains an anionic water-solubilising group, e.g., carboxy, sulphonate, sulphate, phosphate or phosphonate.
The oral care compositions of the present invention may comprise greater than about 50% liquid carrier materials. Water may comprise from about 20% to about 70% or from about 30% to about 50% by weight of the total composition. These amounts of water include the free water which is added plus that which is introduced with other materials such as with sorbitol and with surfactant solutions.
Generally, the liquid carrier may further include one or more humectants. Suitable humectants include glycerin, sorbitol, and other edible polyhydric alcohols, such as low molecular weight polyethylene glycols at levels of from about 15% to about 50%. To provide the best balance of foaming properties and resistance to drying out, the ratio of total water to total humectant may be from about 0.65:1 to about 1.5:1, or from about 0.85:1 to about 1.3:1.
The viscosities of the oral care compositions herein may be affected by the viscosity of Newtonian liquids present in the composition. These may be either pure liquids such as glycerin or water, or a solution of a solute in a solvent such as a sorbitol solution in water. The level of contribution of the Newtonian liquid to the viscosity of the non-Newtonian oral care composition will depend upon the level at which the Newtonian liquid is incorporated. Water may be present in a significant amount in an oral care composition, and has a Newtonian viscosity of approximately 1 mPa·s at 25 deg. C. Humectants such as glycerin and sorbitol solutions typically have a significantly higher Newtonian viscosity than water. As a result, the total level of humectant, the ratio of water to humectant, and the choice of humectants, helps to determine the high shear rate viscosity of the oral care compositions.
Common humectants such as sorbitol, glycerin, polyethyleneglycols, propylene glycols and mixtures thereof may be used, but the specific levels and ratios used will differ depending on the choice of humectant. Sorbitol may be used, but due to its relatively high Newtonian viscosity, in certain embodiments cannot be incorporated at levels above 45% by weight of the composition, as it contributes significantly to the high shear rate viscosity of the oral care composition. Conversely, propylene glycol may be employed at higher levels as it has a lower Newtonian viscosity than sorbitol, and hence does not contribute as much to the high shear rate viscosity of the oral care composition. Glycerin has an intermediate Newtonian viscosity in between that of sorbitol and polyethylene glycol.
Ethanol may also be present in the oral care compositions. These amounts may range from about 0.5 to about 5%, or from about 1.5 to about 3.5% by weight of the total composition. Ethanol can be a useful solvent and can also serve to enhance the impact of a flavour, though in this latter respect only low levels are usually employed. Non-ethanolic solvents such as propylene glycol may also be employed. Also useful herein are low molecular weight polyethylene glycols.
The oral care compositions of the present invention may comprise a dental abrasive, such as those used in dentifrices. Abrasives serve to polish the teeth, remove surface deposits, or both. The abrasive material contemplated for use herein can be any material which does not excessively abrade dentine. Suitable abrasives include insoluble phosphate polishing agents, such as, for example, dicalcium phosphate, tricalcium phosphate, calcium pyrophosphate, beta-phase calcium pyrophosphate, dicalcium phosphate dihydrate, anhydrous calcium phosphate, insoluble sodium metaphosphate, and the like. Also suitable are chalk-type abrasives such as calcium and magnesium carbonates, silicas including xerogels, hydrogels, aerogels and precipitates, alumina and hydrates thereof such as alpha alumina trihydrate, aluminosilicates such as calcined aluminium silicate and aluminium silicate, magnesium and zirconium silicates such as magnesium trisilicate and thermosetting polymerised resins such as particulate condensation products of urea and formaldehyde, polymethylmethacrylate, powdered polyethylene and others such as disclosed in U.S. Pat. No. 3,070,510. Mixtures of abrasives can also be used. The abrasive polishing materials generally have an average particle size of from about 0.1 to about 30 μm, or from about 1 to about 15 μm.
Silica dental abrasives of various types offer exceptional dental cleaning and polishing performance without unduly abrading tooth enamel or dentin. The silica abrasive can be precipitated silica or silica gels such as the silica xerogels described in U.S. Pat. No. 3,538,230, U.S. Pat. No. 3,862,307. Silicas may be used that have an oil absorption from 30 g per 100 g to 100 g per 100 g of silica. It has been found that silicas with low oil absorption levels are less structuring, and therefore do not build the viscosity of the oral care composition to the same degree as those silicas that are more highly structuring, and therefore have higher oil absorption levels. As used herein, oil absorption is measured by measuring the maximum amount of linseed oil the silica can absorb at 25 deg. C.
Suitable abrasive levels may be from about 0% to about 20% by weight of the total composition, in certain embodiments less than 10%, such as from 1% to 10%. In certain embodiments abrasive levels from 3% to 5% by weight of the total composition can be used.
For anticaries protection, a source of fluoride ion will normally be present in the oral care composition. Fluoride sources include sodium fluoride, potassium fluoride, calcium fluoride, stannous fluoride, stannous monofluorophosphate and sodium monofluoro-phosphate. Suitable levels provide from 25 to 2500 ppm of available fluoride ion by weight of the oral care composition.
Suitable chelating agents include organic acids and their salts, such as tartaric acid and pharmaceutically-acceptable salts thereof, citric acid and alkali metal citrates and mixtures thereof. Chelating agents are able to complex calcium found in the cell walls of the bacteria. Chelating agents can also disrupt plaque by removing calcium from the calcium bridges which help hold this biomass intact. However, it is possible to use a chelating agent which has an affinity for calcium that is too high, resulting in tooth demineralisation. In certain embodiments the chelating agents have a calcium binding constant of about 101 to about 105 to provide improved cleaning with reduced plaque and calculus formation. The amounts of chelating that may be used in the formulations of the present invention are about 0.1% to about 2.5%, from about 0.5% to about 2.5% or from about 1.0% to about 2.5%. The tartaric acid salt chelating agent can be used alone or in combination with other optional chelating agents.
Another group of agents particularly suitable for use as chelating agents in the present invention are the water soluble polyphosphates, polyphosphonates, and pyro-phosphates which are useful as anticalculus agents. The pyrophosphate salts used in the present compositions can be any of the alkali metal pyrophosphate salts. An effective amount of pyrophosphate salt useful in the present composition is generally enough to provide at least 1.0% pyrophosphate ion or from about 1.5% to about 6% of such ions. The pyrophosphate salts are described in more detail in Kirk & Othmer, Encyclopedia of Chemical Technology, Second Edition, Volume 15, Interscience Publishers (1968).
Water soluble polyphosphates such as sodium tripolyphosphate, potassium tripolyphosphate and sodium hexametaphosphate may be used. Other long chain anticalculus agents of this type are described in WO98/22079. Also preferred are the water soluble diphosphonates. Suitable soluble diphosphonates include ethane-1-hydroxy-1,1,-diphosphonate (EHDP) and aza-cycloheptane-diphosphonate (AHP). The tripolyphosphates and diphosphonates are particularly effective as they provide both anti-tartar activity and stain removal activity without building viscosity as much as much as less water soluble chemical stain removal agents and are stable with respect to hydrolysis in water. The soluble polyphosphates and diphosphonates are beneficial as destaining actives. Without wishing to be bound by theory, it is believed that these ingredients remove stain by desorbing stained pellicle from the enamel surface of the tooth. Suitable levels of water soluble polyphosphates and diphosphonates are from about 0.1% to about 10%, from about 1% to about 5%, or from about 1.5% to about 3% by weight of the oral care composition.
Still another possible group of chelating agents suitable for use in the present invention are the anionic polymeric polycarboxylates. Such materials are well known in the art, being employed in the form of their free acids or partially or preferably fully neutralised water-soluble alkali metal (e.g. potassium and preferably sodium) or ammonium salts. Additional polymeric polycarboxylates are disclosed in U.S. Pat. No. 4,138,477 and U.S. Pat. No. 4,183,914, and include copolymers of maleic anhydride with styrene, isobutylene or ethyl vinyl ether, polyacrylic, polyitaconic and polymaleic acids, and sulphoacrylic oligomers of MW as low as 1,000 available as Uniroyal ND-2.
Also useful for the present invention are antimicrobial agents. A wide variety of antimicrobial agents can be used, including stannous salts such as stannous pyrophosphate and stannous gluconate; zinc salt, such as zinc lactate and zinc citrate; copper salts, such as copper bisglycinate; quaternary ammonium salts, such as cetyl pyridinium chloride and tetradecylethyl pyridinium chloride; bis-biguanide salts; and nonionic antimicrobial agents such as triclosan. Certain flavour oils, such as thymol, may also have antimicrobial activity. Such agents are disclosed in U.S. Pat. No. 2,946,725 and U.S. Pat. No. 4,051,234. Also useful is sodium chlorite, described in WO 99/43290.
Antimicrobial agents, if present, are typically included at levels of from about 0.01% to about 10%. Levels of stannous and cationic antimicrobial agents can be kept to less than about 5% or less than about 1% to avoid staining problems.
In certain embodiments antimicrobial agents are non-cationic antimicrobial agent, such as those described in U.S. Pat. No. 5,037,637. A particularly effective antimicrobial agent is 2′,4,4′-trichloro-2-hydroxy-diphenyl ether (triclosan).
An optional ingredient in the present compositions is a silicone oil. Silicone oils can be useful as plaque barriers, as disclosed in WO 96/19191. Suitable classes of silicone oils include, but are not limited to, dimethicones, dimethiconols, dimethicone copolyols and aminoalkylsilicones. Silicone oils are generally present in a level of from about 0.1% to about 15%, from about 0.5% to about 5%, or from about 0.5% to about 3% by weight.
Sweetening agents such as sodium saccharin, sodium cyclamate, Acesulfame K, aspartame, sucrose and the like may be included at levels from about 0.1 to 5% by weight. Other additives may also be incorporated including flavours, preservatives, opacifiers and colorants. Typical colorants are D&C Yellow No. 10, FD&C Blue No. 1, FD&C Red No. 40, D&C Red No. 33 and combinations thereof. Levels of the colorant may range from about 0.0001 to about 0.1%.
The oral care composition preferably comprises at least one nucleic acid aptamer at a level where upon directed use, promotes one or more benefits without detriment to the oral cavity component it is applied to. In certain embodiments of the present invention, said oral care composition comprises between about 0.00001% to about 10% of at least one nucleic acid aptamer. In another embodiment, said oral care composition comprises between about 0.00005% to about 5% of at least one nucleic acid aptamer. In another embodiment, said oral care composition comprises between about 0.0001% to about 1% of at least one nucleic acid aptamer.
In another embodiment, an oral care composition comprises at least one peptide aptamer; wherein said at least one peptide aptamer has a binding affinity for an oral cavity component selected from the group consisting of: tooth, enamel, dentin, and any other surfaces in the oral cavity. In another embodiment, said at least one peptide aptamer has a binding affinity for tooth.
The aptamers of the present invention could provide several benefits when bound to an oral cavity component, including, but not limited to, teeth remineralization (e.g. by improving calcium deposition on teeth), teeth acid resistance, appearance and structural changes to teeth, stain prevention (e.g. by repelling teeth staining materials such as dyes or pigments), plaque prevention, tartar prevention, and cavity prevention and treatment. As an example, if aptamers comprising fluorinated nucleotides are degraded or decomposed after binding, they could effectively deliver fluoride ions to teeth, which can provide cavity prevention benefits. Non-limiting examples of fluorinated nucleotides include fluorophosphate nucleotides, 2′-fluoro deoxyribonucleotides, and nucleotides with fluorinated nucleobases.
The combined use of aptamers that bind to different epitopes of a particular target (e.g. tooth) could provide a greater overall target coverage and/or efficacy across different individuals. Identification of aptamers binding to different epitopes can be achieved by performing a covariance analysis for the change in oligonucleotide frequency during the rounds of SELEX selection as described in Example 3. In certain embodiments of the present invention, an oral care composition comprises at least two different nucleic acid aptamers; wherein said at least two different nucleic acid aptamers have binding affinities for different epitopes of tooth. In another embodiment, said at least two different nucleic acid aptamers are selected from the group consisting of SEQ ID NO 1, SEQ ID NO 9, SEQ ID NO 25, SEQ ID NO 112, SEQ ID NO 120, SEQ ID NO 136, and SEQ ID NO 223 to SEQ ID NO 234.
The aptamers of the current invention can also be formulated in oral care products to effectively deliver active ingredients to oral cavity components. In certain embodiments of the present invention, a method for delivering one or more oral care active ingredients to the oral cavity comprises administering an oral care composition comprising at least one nucleic acid aptamer and one or more oral care active ingredients; wherein said at least one nucleic acid aptamer and said one or more oral care active ingredients are covalently or non-covalently attached; and wherein said at least one nucleic acid aptamer has a binding affinity for an oral cavity component. Examples of the oral conditions these oral care active ingredients address include, but are not limited to, appearance and structural changes to teeth, whitening, stain prevention and removal, stain bleaching, plaque prevention and removal, tartar prevention and removal, cavity prevention and treatment, inflamed and/or bleeding gums, mucosal wounds, lesions, ulcers, aphthous ulcers, cold sores, and tooth abscesses.
In another embodiment, said oral cavity component in said method of delivering one or more oral care active ingredients is selected from the group comprising: tooth, enamel, dentin, and any other surfaces in the oral cavity. In another embodiment, said oral cavity component is tooth.
In another embodiment, a method for delivering one or more oral care active ingredients to the oral cavity comprises administering an oral care composition comprising at least one peptide aptamer and one or more oral care active ingredients; wherein said at least one peptide aptamer and said one or more oral care active ingredients are covalently or non-covalently attached; and wherein said at least one peptide aptamer has a binding affinity for an oral cavity component.
In another embodiment, said one or more oral care active ingredients are selected from the group comprising: whitening agents, brightening agents, anti-stain agents, anti-cavity agents, anti-erosion agents, anti-tartar agents, anti-calculus agents, anti-plaque agents, teeth remineralizing agents, anti-fracture agents, strengthening agents, abrasion resistance agents, anti-gingivitis agents, anti-microbial agents, anti-bacterial agents, anti-fungal agents, anti-yeast agents, anti-viral, anti-malodor agents, breath freshening agents, flavoring agents, cooling agents, taste enhancement agents, olfactory enhancement agents, anti-adherence agents, smoothness agents, surface modification agents, anti-tooth pain agents, anti-sensitivity agents, anti-inflammatory agents, gum protecting agents, periodontal actives, tissue regeneration agents, anti-blood coagulation agents, anti-clot stabilizer agents, salivary stimulant agents, salivary rheology modification agents, enhanced retention agents, soft/hard tissue targeted agents, tooth/soft tissue cleaning agents, antioxidants, pH modifying agents, H-2 antagonists, analgesics, natural extracts and essential oils, dyes, optical brighteners, cations, phosphates, fluoride ion sources, peptides, nutrients, enzymes, mouth and throat products, and mixtures thereof. The present invention also includes other oral care active ingredients previously disclosed in the art. In another embodiment, said oral care active ingredient is selected from the group consisting of dyes and optical brighteners. In another embodiment, said oral care active ingredient is selected from the group consisting of dyes and optical brighteners and said at least one nucleic acid aptamer has a binding affinity for tooth.
Non-limiting examples of whitening agents are dyes, optical brighteners, peroxides, metal chlorites, perborates, percarbonates, peroxyacids, and mixtures thereof. Suitable peroxide compounds include hydrogen peroxide, calcium peroxide, carbamide peroxide, and mixtures thereof. Most preferred is carbamide peroxide. Suitable metal chlorites include calcium chlorite, barium chlorite, magnesium chlorite, lithium chlorite, sodium chlorite, and potassium chlorite. Additional whitening actives may be hypochlorite and chlorine dioxide. The preferred chlorite is sodium chlorite.
Dyes and optical brighteners can provide desirable whitening and other cosmetic effects on teeth. Non-limiting examples of dyes are triarylmethane dyes, including brilliant blue FCF (FD&C blue 1 or D&C blue 4), fast green FCF (FD&C green 3), and patent blue V; indigoid dyes, including indigo carmine (FD&C blue 2); anthraquinone dyes, including sunset violet 13 (D&C violet 2); azoic dyes; xanthene dyes; natural dyes, including chlorophylls, spirulina, and anthocyanins; their derivatives; and mixtures thereof.
Optical brighteners, also known as fluorescent whitening agents, are organic compounds that are colorless to weakly colored in solution, absorb ultraviolet light (e.g. from daylight, ca. 300-430 nm), and reemit most of the absorbed energy as blue fluorescent light (400-500 nm). Thus, in daylight, optical brighteners can compensate for the often undesirable yellowish tone found in teeth and other materials. Furthermore, since day UV light (not perceived by the eye) is converted to visible light, the brightness of the teeth can be enhanced to produce a luminous white. Non-limiting examples of optical brighteners are derivatives of carbocyles, stilbene and 4,4′-diaminostilbene, including 4,4′-diamino-2,2′-stilbenedisulfonic acid; derivatives of distyrylbenzenes, distyrylbiphenyls, and divinylstilbenes; derivatives of triazinylaminostilbenes; derivatives of stilbenyl-2H-triazoles; derivatives of benzoxazoles, stilbenylbenzoxazoles, and bis(benzoxazoles); derivatives of furans, benzo[b]furans, benzimidazoles, bix(benzo[b]furan-2-yl)biphenyls, and cationic benzimidazoles; derivatives of 1,3-diphenyl-2-pyrazolines; derivatives of coumarins; derivatives of napthalimides; derivatives of 1,3,5-triazin-2-yl; derivatives of bis(benzoxazol-2-yl); and mixtures thereof. A review of commonly used optical brighteners is found in “Optical Brighteners” by Siegrist, A. E., Eckhardt, C., Kaschig, J. and Schmidt, E.; Ullmann's Encyclopedia of Industrial Chemistry, Wiley and Sons, 2003, the contents of which are incorporated herein by reference. In certain embodiments of the present invention, said oral care active ingredient is 4,4′-diamino-2,2′-stilbenedisulfonic acid.
Non-limiting examples of anti-cavity agents are: a) phosphorus-containing agents, including polyphosphates such as pyrophosphate, tripolyphosphate, trimetaphosphate, and hexametaphosphate; organic phosphates such as glycerophosphate, phytate, 1,6-fructose diphosphate, calcium lactophosphate, casein-phosphopeptide amorphous calcium phosphate (CPP-ACP), and sodium caseinate; phosphoproteins; phosphonates such as ethane hydroxy diphosphonate; and phosphosilicates; b) calcium-containing agents, including calcium lactate; c) anti-microbial agents; d) metals and their cations, including zinc, tin, aluminum, copper, iron, and calcium; e) other organic agents including citrate; and f) fluoride-ion sources agents, including sodium fluoride, stannous fluoride, amine fluorides such as olaflur (amine fluoride 297) and dectaflur, sodium monofluorophosphate, fluorosilicates, fluorozirconates, fluorostannites, fluoroborates, fluorotitanates, and fluorogermanates. Non-limiting examples of cations are Ca²⁺, Sn²⁺, Sn⁴⁺, Zn²⁺, Al³⁺, Cu²⁺, Fe²⁺, and Fe³⁺.
Anti-tartar agents known for use in dental care products also include phosphates, such as pyrophosphates, polyphosphates, polyphosphonates and mixtures thereof. Pyrophosphates are among the best known for use in dental care products. Pyrophosphate ions delivered to the teeth derive from pyrophosphate salts. The pyrophosphate salts useful in the present compositions include the dialkali metal pyrophosphate salts, tetra-alkali metal pyrophosphate salts, and mixtures thereof. Disodium dihydrogen pyrophosphate (Na₂H₂P₂O₇), tetrasodium pyrophosphate (Na₄P₂O₇), and tetrapotassium pyrophosphate (K₄P₂₀₇) in their unhydrated as well as hydrated forms are the preferred species. While any of the above-mentioned pyrophosphate salts may be used, tetrasodium pyrophosphate salt is preferred.
The pyrophosphate salts are described in more detail in Kirk & Othmer, Encyclopedia of Chemical Technology, Third Edition, Volume 17, Wiley-Interscience Publishers (1982). Additional anti-calculus agents include pyrophosphates or polyphosphates disclosed in U.S. Pat. No. 4,590,066 issued to Parran & Sakkab on May 20, 1986; polyacrylates and other polycarboxylates, such as those disclosed in U.S. Pat. No. 3,429,963 issued to Shedlovsky on Feb. 25, 1969, U.S. Pat. No. 4,304,766 issued to Chang on Dec. 8, 1981 and U.S. Pat. No. 4,661,341 issued to Benedict & Sunberg on Apr. 28, 1987; polyepoxysuccinates such as those disclosed in U.S. Pat. No. 4,846,650 issued to Benedict, Bush & Sunberg on Jul. 11, 1989; ethylenediaminetetraacetic acid as disclosed in British Patent No. 490,384 dated Feb. 15, 1937; nitrilotriacetic acid and related compounds as disclosed in U.S. Pat. No. 3,678,154 issued to Widder & Briner on Jul. 18, 1972; polyphosphonates as disclosed in U.S. Pat. No. 3,737,533 issued to Francis on Jun. 5, 1973, U.S. Pat. No. 3,988,443 issued to Ploger, Schmidt-Dunker & Gloxhuber on Oct. 26, 1976 and U.S. Pat. No. 4,877,603 issued to Degenhardt & Kozikowski on Oct. 31, 1989. Anti-calculus phosphates include potassium and sodium pyrophosphates; sodium tripolyphosphate; diphosphonates, such as ethane-1-hydroxy-1,1-diphosphonate, 1-azacycloheptane-1,1-diphosphonate, and linear alkyl diphosphonates; linear carboxylic acids; and sodium zinc citrate.
Agents that may be used in place of or in combination with the pyrophosphate salt include such known materials as synthetic anionic polymers including polyacrylates and copolymers of maleic anhydride or acid and methyl vinyl ether (e.g., Gantrez), as described, for example, in U.S. Pat. No. 4,627,977, to Gaffar et al., as well as, e.g., polyamino propoane sulfonic acid (AMPS), zinc citrate trihydrate, polyphosphates (e.g., tripolyphosphate; hexametaphosphate), diphosphonates (e.g., EHDP; AHP), polypeptides (such as polyaspartic and polyglutamic acids), and mixtures thereof.
Fluoride ion sources are well known for use in oral care compositions as anti-cavity agents. Fluoride ions are contained in a number of oral care compositions for this purpose, particularly dentifrices. Patents disclosing such dentifrices include U.S. Pat. No. 3,538,230 to Pader et al; U.S. Pat. No. 3,689,637 to Pader; U.S. Pat. No. 3,711,604 to Colodney et al; U.S. Pat. No. 3,911,104 to Harrison; U.S. Pat. No. 3,935,306 to Roberts et al; and U.S. Pat. No. 4,040,858 to Wason.
Application of fluoride ions to dental enamel serves to protect teeth against decay. A wide variety of fluoride ion-yielding materials can be employed as sources of soluble fluoride in the instant compositions. Examples of suitable fluoride ion-yielding materials are found in Briner et al; U.S. Pat. No. 3,535,421; issued Oct. 20, 1970 and Widder et al; U.S. Pat. No. 3,678,154; issued Jul. 18, 1972. Preferred fluoride ion sources for use herein include sodium fluoride, potassium fluoride and ammonium fluoride. Sodium fluoride is particularly preferred.
Anti-microbial agents can also be present in the oral care compositions or substances of the present invention. Such agents may include, but are not limited to, triclosan, 5-chloro-2-(2,4-dichlorophenoxy)-phenol, as described in The Merck Index, 11th ed. (1989), pp. 1529 (entry no. 9573) in U.S. Pat. No. 3,506,720, and in European Patent Application No. 0,251,591 of Beecham Group, PLC, published Jan. 7, 1988; chlorhexidine (Merck Index, no. 2090), alexidine (Merck Index, no. 222); hexetidine (Merck Index, no. 4624); sanguinarine (Merck Index, no. 8320); benzalkonium chloride (Merck Index, no. 1066); salicylanilide (Merck Index, no. 8299); domiphen bromide (Merck Index, no. 3411); cetylpyridinium chloride (CPC) (Merck Index, no. 2024; tetradecylpyridinium chloride (TPC); N-tetradecyl-4-ethylpyridinium chloride (TDEPC); octenidine; delmopinol, octapinol, and other piperidino derivatives; nisin preparations; zinc/stannous ion agents; bacteriocins; antibiotics such as augmentin, amoxicillin, tetracycline, doxycycline, minocycline, and metronidazole; and analogs and salts of the above anti-microbial anti-plaque agents; essential oils inclyding thymol, geraniol, carvacrol, citral, hinokitiol, eucalyptol, catechol (particularly 4-allyl catechol) and mixtures thereof; methyl salicylate; hydrogen peroxide; metal salts of chlorite, and mixtures thereof.
Non-limiting examples of flavoring and cooling agents are menthol, menthone, methyl acetate, menthofuran, 1,8-cineol, R-(−)-carvone, limonene, dihydrocarvone, methyl salicylate, sugar alcohols or polyols (e.g. xylitol, sorbitol, and erythritol), and their derivatives. A non-limiting example of teeth remineralizing agents is hydroxyapatite nanocrystals.
Anti-inflammatory agents can also be present in the oral care compositions or substances of the present invention. Such agents may include, but are not limited to, non-steroidal anti-inflammatory agents or NSAIDs such as ketorolac, flurbiprofen, ibuprofen, naproxen, indomethacin, aspirin, ketoprofen, piroxicam and meclofenamic acid. Use of NSAIDs such as ketorolac is claimed in U.S. Pat. No. 5,626,838, issued May 6, 1997. Disclosed therein are methods of preventing and/or treating primary and reoccurring squamous cell carcinoma of the oral cavity or oropharynx by topical administration to the oral cavity or oropharynx an effective amount of an NSAID.
Nutrients may improve the condition of the oral cavity. Nutrients include minerals, vitamins, oral nutritional supplements, enteral nutritional supplements, and mixtures thereof. Minerals that can be included with the compositions of the present invention include calcium, phosphorus, fluoride, zinc, manganese, potassium and mixtures thereof. These minerals are disclosed in Drug Facts and Comparisons (loose leaf drug information service), Wolters Kluer Company, St. Louis, Mo., (c)1997, pp 10-17. Vitamins can be included with minerals or used separately. Vitamins include Vitamins C and D, thiamine, riboflavin, calcium pantothenate, niacin, folic acid, nicotinamide, pyridoxine, cyanocobalamin, para-aminobenzoic acid, bioflavonoids, and mixtures thereof. Such vitamins are disclosed in Drug Facts and Comparisons (loose leaf drug information service), Wolters Kluer Company, St. Louis, Mo., (c)1997, pp. 3-10. Oral nutritional supplements include amino acids, lipotropics, fish oil, and mixtures thereof, as disclosed in Drug Facts and Comparisons (loose leaf drug information service), Wolters Kluer Company, St. Louis, Mo., (c)1997, pp. 54-54e. Amino acids include L-tryptophan, L-lysine, methionine, threonine, levocarnitine or L-carnitine and mixtures thereof. Lipotropics include, but, are not limited to choline, inositol, betaine, linoleic acid, linolenic acid, and mixtures thereof. Fish oil contains large amounts of omega-3 (N-3) polyunsaturated fatty acids, eicosapentaenoic acid and docosahexaenoic acid. Enteral nutritional supplements include, but, are not limited to protein products, glucose polymers, corn oil, safflower oil, medium chain triglycerides as disclosed in Drug Facts and Comparisons (loose leaf drug information service), Wolters Kluer Company, St. Louis, Mo., (c) 1997, pp. 55-57.
Enzymes provide several benefits when used for cleansing of the oral cavity. Proteases break down salivary proteins which are absorbed onto the tooth surface and form the pellicle; the first layer of resulting plaque. Proteases along with lipases destroy bacteria by lysing proteins and lipids which form the structural component of bacterial cell walls and membranes. Dextranases break down the organic skeletal structure produced by bacteria that forms a matrix for bacterial adhesion. Proteases and amylases not only prevent plaque formation but also prevent the development of calculus by breaking-up the carbohydrate-protein complex that binds calcium, preventing mineralization. Enzymes useful in the present invention include any of the commercially available proteases, glucanohydrolases, endoglycosidases, amylases, mutanases, lipases and mucinases or compatible mixtures thereof. Preferred are the proteases, dextranases, endoglycosidases and mutanases, most preferred being papain, endoglycosidase or a mixture of dextranase and mutanase. Additional enzymes suitable for use in the present invention are disclosed in U.S. Pat. No. 5,000,939 to Dring et al.; U.S. Pat. No. 4,992,420 to Neeser; U.S. Pat. No. 4,355,022 to Rabussay; U.S. Pat. No. 4,154,815 to Pader; U.S. Pat. No. 4,058,595 to Colodney; U.S. Pat. No. 3,991,177 to Virda et al. and 3,696,191 to Weeks.
Other materials that can be used with the present invention include commonly known mouth and throat products. Such products are disclosed in Drug Facts and Comparisons (loose leaf drug information service), Wolters Kluer Company, St. Louis, Mo., (c)1997, pp. 520b-527. These products include anti-fungal, antibiotic and analgesic agents.
Antioxidants are generally recognized as useful in compositions such as those of the present invention. Antioxidants are disclosed in texts such as Cadenas and Packer, The Handbook of Antioxidants, (c) 1996 by Marcel Dekker, Inc. Antioxidants that may be included in the oral care composition or substance of the present invention include, but are not limited to vitamin E, ascorbic acid, uric acid, carotenoids, Vitamin A, flavonoids and polyphenols, herbal antioxidants, melatonin, aminoindoles, lipoic acids and mixtures thereof.
In another embodiment, a method for delivering one or more oral care active ingredients to the oral cavity comprises administering an oral care composition comprising: at least one nucleic acid aptamer and one or more nanomaterials; wherein said at least one nucleic acid aptamer and said one or more nanomaterials are covalently or non-covalently attached; and wherein said at least one nucleic acid aptamer has a binding affinity for an oral cavity component.
In another embodiment, a method for delivering one or more oral care active ingredients to the oral cavity comprises administering an oral care composition comprising: a) at least one nucleic acid aptamer; b) one or more nanomaterials; and c) and one or more oral care active ingredients; wherein said at least one nucleic acid aptamer and said one or more nanomaterials are covalently or non-covalently attached; and wherein said at least one nucleic acid aptamer has a binding affinity for an oral cavity component. In another embodiment, said one or more oral care active ingredients are covalently or non-covalently attached to said one or more nanomaterials. In yet another embodiment, said one or more oral care active ingredients are carried by said one or more nanomaterials.
Non-limiting examples of nanomaterials are gold nanoparticles, nano-scale iron oxides, carbon nanomaterials (such as single-walled carbon nanotubes and graphene oxide), mesoporous silica nanoparticles, quantum dots, liposomes, poly (lactide-co-glycolic acids) nanoparticles, polymeric micelles, dendrimers, serum albumin nanoparticles, and DNA-based nanomaterials.
In addition to at least one nucleic acid aptamer, the oral care compositions of the present invention may also include surfactants and/or detergents, polishing agents, abrasive materials, binders, carriers, thickening agents, humectants, salts, and other ingredients. Surfactants or detergents can provide a desirable foaming quality. Suitable surfactants are those which are reasonably stable and foam throughout a wide pH range. The surfactant may be anionic, nonionic, amphoteric, zwitterionic, cationic, or mixtures thereof. Anionic surfactants useful herein include the water-soluble salts of alkyl sulfates having from 8 to 20 carbon atoms in the alkyl radical (e.g., sodium alkyl sulfate) and the water-soluble salts of sulfonated monoglycerides of fatty acids having from 8 to 20 carbon atoms. Sodium lauryl sulfate and sodium coconut monoglyceride sulfonates are examples of anionic surfactants of this type. Other suitable anionic surfactants are sarcosinates, such as sodium lauroyl sarcosinate, taurates, sodium lauryl sulfoacetate, sodium lauroyl isethionate, sodium laureth carboxylate, and sodium dodecyl benzenesulfonate. Mixtures of anionic surfactants can also be employed. Many suitable anionic surfactants are disclosed by Agricola et al., U.S. Pat. No. 3,959,458, issued May 25, 1976, incorporated herein in its entirety by reference. Nonionic surfactants which can be used in the compositions of the present invention can be broadly defined as compounds produced by the condensation of alkylene oxide groups (hydrophilic in nature) with an organic hydrophobic compound which may be aliphatic or alkyl-aromatic in nature. Examples of suitable nonionic surfactants include poloxamers (sold under trade name Pluronic), polyoxyethylene, polyoxyethylene sorbitan esters (sold under trade name Tweens), fatty alcohol ethoxylates, polyethylene oxide condensates of alkyl phenols, products derived from the condensation of ethylene oxide with the reaction product of propylene oxide and ethylene diamine, ethylene oxide condensates of aliphatic alcohols, long chain tertiary amine oxides, long chain tertiary phosphine oxides, long chain dialkyl sulfoxides, and mixtures of such materials. The amphoteric surfactants useful in the present invention can be broadly described as derivatives of aliphatic secondary and tertiary amines in which the aliphatic radical can be a straight chain or branched and wherein one of the aliphatic substituents contains from about 8 to about 18 carbon atoms and one contains an anionic water-solubilizing group, e.g., carboxylate, sulfonate, sulfate, phosphate, or phosphonate. Other suitable amphoteric surfactants are betaines, specifically cocamidopropyl betaine. Mixtures of amphoteric surfactants can also be employed. Many of these suitable nonionic and amphoteric surfactants are disclosed by Gieske et al., U.S. Pat. No. 4,051,234, issued Sep. 27, 1977, incorporated herein by reference in its entirety. The present composition typically comprises one or more surfactants each at a level of from about 0.25% to about 12%, preferably from about 0.5% to about 8%, and most preferably from about 1% to about 6%, by weight of the composition.
The binder system, generally, is a primary factor that determines the rheological characteristics of the oral care composition. The binder also acts to keep any solid phase of an oral care component suspended, thus preventing separation of the solid phase portion of the oral care component from the liquid phase portion. Additionally, the binder can provide body or thickness to the oral care composition. Thus, in some instances, a binder can also provide a thickening function to an oral care composition. Examples of binders include sodium carboxymethyl-cellulose, cellulose ether, xanthan gum, carrageenan, sodium alginate, carbopol, or silicates such as hydrous sodium lithium magnesium silicate. Other examples of suitable binders include polymers such as hydroxypropyl methylcellulose, hydroxyethyl cellulose, guar gum, tragacanth gum, karaya gum, arabic gum, Irish moss, starch, and alginate. Alternatively, the binder can include a clay, for example, a synthetic clay such as a hectorite, or a natural clay. Each of the binders can be used alone or in combination with other binders.
Non-limiting examples of thickening agents include thickening silica, polymers, clays, and combinations thereof. Thickening silica, for example, SILODENT 15 hydrated silica, in the amount between about 4% to about 8% by weight (e.g., about 6%) provide desirable in-mouth characteristics. The phrase “in-mouth characteristics” as described herein relates to the body and thickness of the dentifrice as it foams in the mouth of a user.
Non-limiting examples of polishing agents include abrasive materials, such as carbonates (e.g., sodium bicarbonate, calcium carbonate) water-colloidal silica, precipitated silicas (e.g., hydrated silica), sodium aluminosilicates, silica grades containing alumina, hydrated alumina, dicalcium phosphates, calcium hydrogen phosphates, calcium pyrophosphate, calcium pyrophosphate (beta phase), hydroxyapatite, insoluble sodium metaphosphate, and magnesiums (e.g., trimagnesium phosphate). A suitable amount of polishing agent is an amount that safely provides good polishing and cleaning and which, when combined with other ingredients gives a smooth, flowable, and not excessively gritty composition. In general, when polishing agents are included, they are present in an amount from about 5% to about 50% by weight (e.g., from about 5% to about 35%, or from about 7% to about 25%).
Examples of carriers include water, polyethylene glycol, glycerin, polypropylene glycol, starches, sucrose, alcohols (e.g., methanol, ethanol, isopropanol, etc.), or combinations thereof. Examples of combinations include various water and alcohol combinations and various polyethylene glycol and polypropylene glycol combinations. In general, the amount of carrier included is determined based on the concentration of the binder system along with the amount of dissolved salts, surfactants, and dispersed phase.
Generally, humectants are polyols. Examples of humectants include glycerin, sorbitol propyleneglycol, xylitol, lactitol, polypropylene glycol, polyethylene glycol, hydrogenated corn syrup and mixtures thereof. In general, when humectants are included they can be present in an amount from about 10% to about 60% by weight.
Examples of buffers and salts include primary, secondary, or tertiary alkali metal phosphates, citric acid, sodium citrate, sodium saccharin, tetrasodium pyrophosphate, sodium hydroxide, and the like. The oral care compositions of the present invention may also include active ingredients, for example, to prevent cavities, to whiten teeth, to freshen breath, to deliver oral medication, and to provide other therapeutic and cosmetic benefits such as those described above. Examples of active ingredients include the following: anti-caries agents (e.g., water soluble fluoride salts, fluorosilicates, fluorozirconates, fluorostannites, fluoroborates, fluorotitanates, fluorogermanates, mixed halides and casine); anti-tartar agents; anti-calculus agents (e.g. alkali-metal pyrophosphates, hypophosphite-containing polymers, organic phosphocitrates, phosphocitrates, polyphosphates); anti-bacterial agents (e.g., bacteriocins, antibodies, enzymes); anti-bacterial enhancing agents; anti-microbial agents (e.g., Triclosan, chlorhexidine, copper-, zinc- and stannous salts such as zinc citrate, zinc sulfate, zinc glycinate, sanguinarine extract, metronidazole, quaternary ammonium compounds, such as cetylpyridinium chloride; bis-guanides, such as chlorhexidine digluconate, hexetidine, octenidine, alexidine; and halogenated bisphenolic compounds, such as 2,2′ methylenbis-(4-chloro-6-bromophenol)); desensitizing agents (e.g., potassium citrate, potassium chloride, potassium tartrate, potassium bicarbonate, potassium oxalate, potassium nitrate and strontium salts); whitening agents (e.g., bleaching agents such as peroxy compounds, e.g. potassium peroxydiphosphate); anti-plaque agents; gum protecting agents (e.g., vegetable oils such as sunflower oil, rape seed oil, soybean oil and safflower oil, and other oils such as silicone oils and hydrocarbon oils). The gum protection agent may be an agent capable of improving the permeability barrier of the gums. Other active ingredients include wound healing agents (e.g., urea, allantoin, panthenol, alkali metal thiocyanates, chamomile-based actives and acetylsalicylic acid derivatives, ibuprofen, flurbiprofen, aspirin, indomethacin etc.); tooth buffering agents; demineralization agents; anti-inflammatory agents; anti-malodor agent; breath freshing agents; and agents for the treatment of oral conditions such as gingivitis or periodontitis.
The oral care compositions of the present invention may also include one or more of other ingredients, comprising: phenolic compounds (e.g., phenol and its homologues, including 2-methyl-phenol, 3-methyl-phenol. 4-methyl-phenol, 4-ethyl-phenol, 2,4-dimethol-phenol, and 3,4-dimethol-phenol); sweetening agents (e.g., sodium saccharin, sodium cyclamate, sucrose, lactose, maltose, and fructose); flavors (e.g., peppermint oil, spearmint oil, eucalyptus oil, aniseed oil, fennel oil, caraway oil, methyl acetate, cinnamaldehyde, anethol, vanillin, thymol and other natural or nature-identical essential oils or synthetic flavors); preservatives (e.g., p-hydroxybenzoic acid methyl, ethyl, or propyl ester, sodium sorbate, sodium benzoate, bromochlorophene, triclosan, hexetidine, phenyl silicylate, biguanides, and peroxides); opacifying and coloring agents such as titanium dioxide or FD&C dyes; and vitamins such as retinol, tocopherol or ascorbic acid.
An example of synthesizing aptamers that can be used in oral care compositions, such as dentifrice, is shown below.

Aptamer Preparation:

Aptamers SEQ ID NO 1, SEQ ID NO 9, and SEQ ID NO 25 are synthesized by enzymatic transcription from the corresponding double stranded DNA templates using a mixture of 15 mM 2′-fluoro CTP, 15 mM 2′-fluoro UTP, 5 mM ATP, 5 mM GTP, a mutant T7 polymerase (T7 R&DNA), and other standard reagents are used. The aptamers are then cleaned up with a Zymo RNA cleanup column, following manufacturer's instructions, and eluted on the reaction buffer (e.g. phosphate buffered saline (PBS) with EDTA: 10 mM sodium phosphate, 0.15 M NaCl, 10 mM EDTA, pH 7.2).

Conjugation Reaction:

First, a solution of 4,4′-diamino-2,2′-stilbenedisulfonic acid (0.25 M) and imidazole (0.1 M) in water (pH 6) is prepared. Then, EDC (1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride) is weighed in a reaction vial and mixed with an aliquot of an aptamer solution prepared as above. An aliquot of the amine/imidazole solution is added immediately to the reaction vial and vortexed until all the components are dissolved. An additional aliquot of imidazole solution (0.1 M, pH 6) is added to the reaction vial and the reaction mixture is incubated at room temperature for at least 2 hours. Following incubation, the unreacted EDC and its by-products and imidazole are separated from the modified aptamer by dialysis or by using a spin desalting column and a suitable buffer (e.g. 10 mM sodium phosphate, 0.15 M NaCl, 10 mM EDTA, pH 7.2). Additional details about the conjugation protocols are described in “Hermanson G. T. (2008). Bioconjugate Techniques. 2nd Edition. pp. 969-1002, Academic Press, San Diego.”, the content of which is incorporated herein by reference.
The produced modified aptamer is conjugated with 4,4′-diamino-2,2′-stilbenedisulfonic acid at the 5′-end and can be formulated in an oral care composition (e.g. dentifrice) to provide teeth whitening benefits when contacted with teeth.
An example of a potential dentifrice formulation comprising one or more aptamers of the present invention is shown below in TABLE 1. Sample dentifrice formulations can be prepared using standard methods known in the art using the components listed in TABLE 1.

	TABLE 1

		Weight % of
	Components	Composition

	Sorbitol solution (70%)	32.577
	Sodium hydroxide (50% soln.)	1.740
	Water	QS
	Saccharin sodium	0.450
	Xanthan gum	0.300
	Sodium fluoride	0.243
	Carboxymethylcellulose	1.050
	Sodium acid pyrophosphate	3.190
	Carbomer	0.300
	Flavor	1.4
	Sodium lauryl sulfate (28% soln.)	6.000
	Mica titanium dioxide	0.400
	Aptamer	0.1-0.01
	Silica	22
	Total	100

EXAMPLES

Example 1. Aptamers Design

A. Preparation of the Immobilization Field

The immobilization field was prepared by synthesizing a random library of eight nucleotide oligonucleotides with a disulfide group on the 5′-end (immobilization field library) as described elsewhere (PLoS One. 2018 Jan. 5; 13(1):e0190212). In brief, the 8-mer thiolated random oligonucleotide library was dissolved in 50 μL of 1×PBS buffer (pH 7.4) at a final concentration of 10 μM. The surface of a gold coated glass slide with dimensions of 7 mm×10 mm×0.3 mm (Xantec, Germany). was treated with five sequential 10 μL drops of the immobilization field library. The slide was then allowed to incubate for 1 hour in the dark at room temperature in order to facilitate conjugation of the immobilization field library onto the gold surface.
After this incubation period, the immobilization field library was considered to have been conjugated onto the gold surface. The remaining solution was removed, and the surface was allowed to dry at room temperature.
The remaining surface was then blocked with short thiol terminated polyethylene glycol (PEG-SH) with molecular formula: CH₃O—(CH₂CH₂O)_n—CH₂CH₂SH and an average molecular weight of 550 daltons. An aliquot of 50 μL of the PEG-SH solution in 1×PBS buffer at a concentration of 286 μM was applied to the chip and allowed to incubate overnight at room temperature with gentle shaking. This process was repeated in a second blocking step, with an incubation period of 30 minutes at room temperature with gentle shaking.
Following blocking of the chip, the latter was washed with 600 μL of 1×HEPES buffer (10 mM HEPES, pH 7.4, 120 mM NaCl, 5 mM KCl, 5 mM MgCl₂) for 5 minutes with shaking at room temperature.

B. Library Preparation

A DNA library of about 10¹⁵different sequences, containing a random region of 40 nucleotides flanked by two conserved regions, i.e. T7 promoter sequence at the 5′-end (5′-GGGAAGAGAAGGACATATGAT-3′) and a 3′ reverse primer recognition sequence (5′-TTGACTAGTACATGACCACTT-3′), was transcribed to RNA using a mixture of 3:1 2′-fluoro pyrimidines nucleotides and natural purine nucleotides and a mutant T7 polymerase (T7 R&DNA).
An aliquot of the transcribed selection library comprising about 10¹⁵RNA sequences was diluted in 50 μL of 1× selection buffer (10 mM cacodylate buffer, 120 mM NaCl, 5 mM KCl, 50 μM SnF₂). An equimolar number of oligonucleotides complementary to the conserved regions of the library sequences (T7 promoter primer and 3′ reverse primer) or blockers was added and incubated with the selection library in a total volume of 100 μL. This solution was heated for 10 minutes at 45° C. to ensure removal of any secondary or tertiary structures which could interfere with the proper annealing of the blockers to the selection library. The blockers were then allowed to anneal to the selection library by allowing the mixture to equilibrate to room temperature for 15 minutes.
This blocked selection library was then exposed to the immobilization field in five sequential 10 μL drops. The blocked selection library was incubated on the immobilization field for 30 minutes with slow shaking in an incubator at room temperature. The solution remaining on top after this time period was removed and discarded. The chip was washed twice with the addition of 50 μL of selection buffer. The buffer was pipetted over the chip and then discarded.
The blocked selection library sequences which were bound to the immobilization field were recovered from the chip by applying 50 μL of 60% DMSO and incubating for 10 min at room temperature. The solution was removed to a fresh tube, and the process was repeated two more times. The three elution solutions were combined (150 μL in total). The RNA sequences were then cleaned up with a Zymo RNA cleanup column (Zymo Research, Irvine, Calif.), following manufacturer's instructions. The purified selection library was eluted with 35 μL of water and combined with 10 μL of 5× selection buffer and 5 μL of 500 μM SnF₂.

C. Aptamer Selection

A clean unerupted third molar tooth was washed with three successive applications of 1 mL water and dipped into a sample of human saliva collected from several individuals. Saliva was pipetted over regions of the tooth that appeared to not be coated. The 50 μL library solution prepared as described above (section B) was pipetted into a depression on a microscope slide (concavity slides, 3.2 mm thick; United Scientific) and the tooth was placed in this depression. The slide was then placed in a shaking incubator at 50 rpm, 37° C., for 1 hour. The tooth was removed and washed twice with 1 mL each of selection buffer. Then the tooth was placed on a fresh depression slide and 50 μL of 60% DMSO was added to elute bound sequences. This elution process was repeated and the two elution solutions were combined (100 μL in total). The eluted RNA library was cleaned up with a Zymo RNA clean up column, following manufacturer's instructions. The library was reverse transcribed into DNA with Protoscript RT II enzyme and PCR amplified in a two-step process. First, four separate PCR reactions were performed with different numbers of sequential PCR cycles (e.g. 4, 6, 8, and 10 cycles). Then, the products of each of these PCR reactions were analyzed by gel electrophoresis to determine the optimum number of cycles required for amplification, i.e. as high a yield as possible without the appearance of any concatemers of the PCR product. Then, this number of PCR cycles was applied for library amplification to complete the selection round.
The library was split into two aliquots to perform two experiments under the same conditions (Experiment A and Experiment B). The selection process was repeated eleven more times. Dentifrice (Crest Cavity Protection) was added at a concentration of 0.322% in the selection buffer during selection rounds 6, 9, and 12.
Negative selections against coffee and wine were also performed. During selection rounds 7 and 10, an aliquot of 5 μL of instant coffee was added to the library solution (for a final 1:10 dilution) and the mixture was incubated with the immobilization field for 30 minutes with shaking in an incubator at room temperature. Oligonucleotides with specificity for molecules present in the coffee are not expected to bind the immobilization field. Thus, the solution remaining on top after this time period was removed and discarded. The chip was washed twice with the addition of 50 μL of selection buffer. The buffer was pipetted onto the surface and then discarded. The library sequences which were bound to the immobilization field were recovered from the chip by applying 50 μL of 60% DMSO and incubating for 10 min at room temperature. The solution was removed to a fresh tube, and the process was repeated two more times. The three elution solutions were combined (150 μL in total). The RNA sequences were then cleaned up with a Zymo RNA cleanup column, following manufacturer's instructions. The library was reverse transcribed into DNA with Protoscript RT II enzyme and PCR amplified in a two-step process, as described above, to complete the selection cycle. The same process was performed with wine during selection rounds 8 and 11.

D. Aptamers Sequencing

Aliquots of selection rounds 7 to 12 for both experiments were prepared for next generation sequencing (NGS) analysis. A total of more than 23 million sequences were analyzed. The number of sequences captured was much lower for selection rounds 11 and 12 as a function of the increased stringency of selection. One indication that a selection was successful is the observation that the copy number of certain sequences increased over selection rounds (see FIG. 1 and FIG. 2). In the graphs shown in FIGS. 1 and 2, the top 20 sequences based on the frequency on round 12 of the selection process were graphed. For instance, for FIG. 1, the sequences are OC1R-A1 to OC1R-A20 in order from the top line to the bottom line (based on round 12). FIG. 1 shows the enrichment trajectories of the top twenty sequences in terms of copy number across different selection rounds for Experiment A. FIG. 2 shows the enrichment trajectories of the top twenty sequences in terms of copy number across different selection rounds for Experiment B. The top sequences in terms of copy number for every selection experiment are listed in TABLE 2. Interestingly, the top 15 sequences, based on copy number, in selection experiment A were also identified in the top 40 sequences of selection experiment B. Furthermore, the top 2 sequences in both experiments were identical, but in the reverse ranking.

Example 2. RNA Aptamers Binding

DNA oligonucleotides encoding for selected aptamers (OC1R-B1/OC1R-A2,OC1R-B9, and OC1R-B25/OC1R-A9) and one encoding for a negative control aptamer (Neg) were transcribed to RNA using a mixture of 1 mM biotinylated UTP, 15 mM 2′-fluoro CTP, 14 mM 2′-fluoro UTP, 5 mM ATP, 5 mM GTP, a mutant T7 polymerase (T7 R&DNA), and other standard reagents. The modified RNA oligonucleotides were then cleaned up with a Zymo RNA cleanup column, following manufacturer's instructions. An aliquot of 250 μL of 1 μM modified RNA in 1× binding buffer (10 mM cacodylate buffer, 120 mM NaCl, 5 mM KCl, 50 μM SnF₂, and 0.322% dentifrice) was placed in the depression of a microscope slide (concavity slides, 3.2 mm thick; United Scientific, Waukegan, Ill.). Separately, a clean unerupted third molar tooth was washed with water, dried, and coated with human saliva collected fresh from several. The tooth was then placed into the depression of the slide containing the modified RNA and incubated for 30 minutes at room temperature. The tooth was removed from the slide and washed twice with 250 μL of binding buffer.
A solution of streptavidin-horse radish peroxidase (HRP) in binding buffer was prepared and an aliquot of 250 μL was placed into the depression of a clean slide (concavity slides, 3.2 mm thick; United Scientific). The tooth was also placed into the same depression and incubated for 30 minutes at room temperature. After incubation, the tooth was washed with 2 mL of binding buffer. Finally, to detect aptamer binding, the tooth was immersed into a solution of 10× LumiGLO® (Cell Signaling Technology, Danvers, Mass.) and 10× hydrogen peroxide (50:50 mixture of 20× stocks). Only aptamers that bind to the tooth generated chemoluminescence in darkness (see FIGS. 3A-3D). FIGS. 3A-3D show the binding of different aptamers to teeth as demonstrated by the chemoluminescence of the teeth in darkness. FIG. 3A shows a negative control. FIG. 3B shows the binding of the aptamer identified as “OC1R-B1” to teeth. FIG. 3C shows the binding of the aptamer identified as “OC1R-B9” to teeth. FIG. 3D shows the binding of the aptamer identified as “OC1R-B25/OC1R-A9” to teeth.

Example 3. Covariance Analysis of Sequences

A covariance analysis for the change in sequence frequency was performed on the top 100 aptamers of Experiment B. First, for each selection round, the frequency data was normalized by dividing the observed frequency of each aptamer by the average of the frequencies of the top 100 aptamers. This normalization allowed eliminating potential differences caused by PCR amplification prior to NGS analysis among different selection rounds. Then, the normalized values of each aptamer in selection round 7 were subtracted from the normalized values of the corresponding aptamer in selection rounds 8 to 12. The resulting matrix was used for the correlation analysis.
A Pearson correlation across the selection rounds was performed. Since a different tooth was used in each selection round, it is reasonable to assume that the covariance among aptamer frequencies would be due to covariance in the abundance of the epitope within the tooth that they bind to. Thus, each cluster of covarying aptamers corresponds to a group of aptamers that bind to a different epitope within the tooth. An Euclidean distance matrix from the correlation matrix was generated and used as the basis for clustering with a Ward.D2 algorithm (see FIG. 4). FIG. 4 shows a correlation matrix ordered by clustering (Ward.D2 method) for enrichment trajectories of top 100 aptamers of Experiment B. These analyses were performed with the software R.
Based on FIG. 4, five different epitopes are likely the binding sites of the selected aptamers. The sequences numbers (SEQ ID NOs) of such aptamers for each cluster/epitope are listed below:

Cluster A: 29, 66, 4, 89, 3, 31, 1, 49, 69, 75, 81, 5, 41, 37, 6, 8, 14, 21, 61

Cluster B: 16, 24, 33, 76, 45, 36, 52, 51, 15, 93

Cluster C: 87, 9, 62, 77, 79, 35, 73, 7, 78, 98, 55, 59, 71, 18, 95, 53, 13, 20, 23, 30, 84, 22, 34

Cluster D: 12, 17, 11, 39, 82, 27, 10, 26, 38, 92, 65, 56, 88, 42, 47, 28, 63, 91, 32, 96, 46, 60

Cluster E: 99, 43, 80, 100, 44, 97, 58, 67, 74, 85, 86, 19, 90, 50, 25, 83, 54, 40, 48, 72, 64, 57, 68, 94, 2, 70

The covariance analysis suggests that aptamers OC1R-B1 (SEQ ID NO 1), OC1R-B9 (SEQ ID NO 9), and OC1R-B25/OC1R-A9 (SEQ ID NO 25) bind to different epitopes within a tooth. Furthermore, aptamers within cluster A likely bind to the same epitope as OC1R-B1, aptamers within cluster C likely bind to the same epitope as OC1R-B9, and aptamers within cluster E likely bind to the same epitope as OC1R-B25 (or OC1R-A9). Aptamers in clusters B and D probably bind to epitopes different than the aptamers described above.
It should be noted that a significant negative correlation among clusters was observed, which could be caused by the variation in the chemical composition of the enamel of the teeth used in this study. This variation could be due to either natural variation among individuals from whom the teeth were extracted or differences on post-extraction treatment of the teeth.
The combined use of aptamers from different clusters could provide a greater overall tooth coverage and/or efficacy across different individuals and it is included as one of the embodiment of the present invention. Aptamers binding to different teeth epitopes can be selected using the information from this example. Furthermore, the use of these aptamers could be used to diagnose the chemical composition of teeth enamel in vivo.

Example 4. Motif and Predicted Structure Analysis

Aptamers bind to target molecules on the basis of the lowest free-energy shape that they form. The lowest free energy shape is a function of homology between regions within the single stranded sequence. These regions of homology fold back onto each other and thus create the secondary and tertiary shape of the aptamer that is crucial to enable binding. We characterized the core characteristics of these aptamers through a combined analysis of conserved motif sequences and their effect on the predicted structure of the whole aptamer. A motif in this context is defined as a contiguous sequence of nucleotides of a defined length. For this example, we considered each possible overlapping six nucleotide motif within the random region of each aptamer characterized.
The frequency of motifs of six or more nucleotides from the random regions of aptamers OC1R-B1, OC1R-B9, and OC1R-A9 within a subset of the selection library (top 1,000 oligonucleotides in terms of copy number) was determined. Since these aptamers were all selected for binding to the same target (teeth), it stands to reason that motifs within this library that were present at higher frequencies than a random distribution would represent key sequences within the aptamers that were selected for. Moreover, predicted structures containing these sequences should be reasonably expected to represent structures that have been selected for. As such, an analysis of the selection of motif sequences and the predicted structures that they form provides a basis for a more general understanding of the necessary requirements for aptamers that have the capacity to bind to teeth.
The prediction of the secondary structures of the aptamers was performed with RNAstructure (https://rna.urmc.rochester.edu/RNAstructureWeb/Servers/Predictl/Predictl.html).
A. Analysis of the Role of Conserved Motifs on Structure within the Aptamer OC1R-B1:
The results of motif analysis are presented in FIG. 5. The overlapping six nucleotide motifs comprising the random region of the aptamer are provided consecutively along the x axis in this figure. The y axis provides a statistical significance (Z value) for each motif in the library. The Z value was computed as the observed frequency of this motif in the library minus the average of the frequency for all motifs in the library and this subtractant was divided by the standard deviation of all motifs in the library to provide the Z value. Thus, a Z value of 2 represents a frequency of this motif in the library that is two standard deviations greater than the average value for all motifs.
In FIG. 5, it is clear that the sequence UUCCUA and the sequence UUUAUCUU were conserved at a level that represented more than two standard deviations from the average. These two conserved sequences were separated by a G and U consecutively that were not conserved. These two consensus sequences can be joined by considering these non-conserved nucleotides as N's.
SEQ ID NO 235:

5′ UUCCUANNUUUAUCUU 3′.
The lowest free energy predicted structure of the OC1R-B1 aptamer is shown in FIG. 6. The numbers in FIGS. 6, 8, 10, 11, 12, 18A-18D, 19A-19C, 20A and 20B indicate the position along the sequence from the 5′-end to the 3′-end; and are useful to track and align oligos. It appears that the consensus motif is key to the creation of a small loop between stems, as well as the joining of the two ends of the aptamer. The sequence of the stem (double stranded regions) itself is of importance as alteration of this sequence while maintaining double stranded structure can destroy binding capacity. It is thought that the sequence nature of the double stranded region is important in terms of the stacking energy of the bases and that this stacking energy is affected by events such as binding elsewhere in the aptamer. The conserved motif noted as SEQ ID NO 235 is highlighted in a box. SEQ ID NO's 235 to 244 are shown in TABLE 5.
Given that we have shown that the DNA version of this aptamer also binds effectively to teeth (see Example 7), it stands to reason that the conclusions arrived at within this example regarding conserved motifs in the RNA sequence would apply to the DNA sequence as well. Thus, any sequences containing the corresponding deoxyribonucleotide motif
SEQ ID NO 236:

5′-TTCCTANNTTTATCTT-3′

are also expected to bind to teeth and are included as embodiments of the present invention.
B. Analysis of the Role of Conserved Motifs on Structure within the Aptamer OC1R-B9:
The analysis of the role of conserved motifs on structure within aptamer OC1R-B9 was performed in a manner identical to that described for OC1R-B1. FIG. 7 provides a summary of the motif analysis for aptamer OC1R-B9. There is a ten nucleotide motif near the 5′ end of the aptamer that was present at a frequency that was more than two standard deviations from the overall average motif frequency in the selected libraries,
SEQ ID NO 237:

5′-UUCGCANAAG-3′.

This sequence has a single degenerate nucleotide within it. There is an additional highly conserved 14 nucleotide motif near the 3′ end of the random sequence,
SEQ ID NO 238:

5′-UGCGGCANGCGCGU-3′.
This sequence also contains one degenerate nucleotide. The predicted secondary structure of OC1R-B9 and its conserved motifs is illustrated in FIG. 8. It is clear in this figure that the two consensus motifs are related to each other, each comprising a different side of the same double stranded secondary structure. Sequences containing any of these motifs are also expected to bind to teeth and are included as embodiments of the present invention. Given that we demonstrated that the DNA version of this aptamer also bound to teeth, it stands to reason that the same consensus motifs within the DNA version of this aptamer would be necessary core elements for the binding function. Thus, any sequences containing any of the corresponding deoxyribonucleotide motifs:
SEQ ID NO 239:

5′-TTCGCANAAG-3′

SEQ ID NO 240:

5′-TGCGGCANGCGCGT-3′

are also expected to bind to teeth and are included as embodiments of the present invention.
C. Analysis of the Role of Conserved Motifs on Structure within Aptamer OC1R-A9:
The motif analysis and predicted secondary structure for the aptamer OC1R-A9 were performed in a manner identical to that described for aptamer OC1R-B1 and OC1R-B9. The motif analysis for the aptamer OC1R-A9 is provided in FIG. 9. In FIG. 9, as described in Section A above, the y axis provides a statistical significance (Z value) for each motif in the library. The Z value was computed as the observed frequency of this motif in the library minus the average of the frequency for all motifs in the library and this subtractant was divided by the standard deviation of all motifs in the library to provide the Z value.” The ten nucleotide motif,
SEQ ID NO 241:

5′-CUUUUCUUCC-3′

was present at a frequency that was more than two standard deviations from the overall average frequency of motifs within this selected library. The role of this motif on the structure of the aptamer is provided in FIG. 10. It is clear that this motif is responsible for the formation of a double stranded region within the aptamer. Therefore, it stands to reason that this double stranded region within the aptamer is necessary for binding to teeth. This motif within the DNA version of this aptamer, OC1D-A9 is also responsible for the formation of a double stranded region (FIG. 11). Therefore, sequences containing this motif are also expected to bind to teeth and are included as embodiments of the present invention. Therefore, it stands to reason that any DNA sequences containing the corresponding deoxyribonucleotide motif
SEQ ID NO 242:

5′-CTTTTCTTCC-3′

are also expected to bind to teeth and are included as embodiments of the present invention.
D. Analysis of Common Motifs within Aptamer Library:
A search for common motifs within the top 10,000 sequences in terms of frequency from Experiment B was performed. The lead motif identified in terms of significant deviation from random distribution was SEQ ID NO 243.
SEQ ID NO 243:

5′-GCGCGCGC-3′

This motif was found in each of the following sequences, in which the 5′- and 3′-primer recognition sequences were eliminated for simplicity. Oligonucleotides comprising the motif SEQ ID NO 243 are included as an embodiment of the current invention.

	OC1R-B71
	AAGCCGGCCCGGGAACAUGUCACGCGCGCGCGCAAAGUAG

	OC1R-B125
	GAAUUAUGAUAGACUAUGAGUCAAUAGCGCGCGCUGGAGG

	OC1R-B181
	CACCGGGUGACGAAACGGCGCGCGCGCUAGCCUGCUAGCA

	OC1R-B190
	ACACCGAGGGACUGAAUGGGGAGGCCGCGCGCGCUGAGGG

	OC1R-B302
	AAGUCAGGACGCGAUGGGUGCGCGCGCGCGUGCGACAUAA

	OC1R-B306
	ACGGCGCGCGCAGGCUACCACUACUGACUCGGCAAUGAUA

	OC1R-B316
	CAACACUGCGCGCGCCGGACAACAAGCGAUUCCUGAGUAC

	OC1R-B317
	CAACUCGACCUGCGCGCGCCUACCCCCAAACUCAACUACC

	OC1R-B338
	CGAGGGUUAGAUCGGGGCGCGCGCACUUGUGGUUGUCCAA

	OC1R-B348
	GAACGAGAGGCGCGCGCUGGUGGACCGGGGGAUAGGGGAU

	OC1R-B390
	AACCGGUCAACACGAUCCUGAGCGCGCGCACGGAUGAAUU

	OC1R-B394
	AACGGGCAUGACAGCCUCACGCCAAGGCGCGCGCGGGUAA

	OC1R-B395
	AACGUCAAAAAACACUGCGCGCGCUGGAUAGAUGAACGUA

	OC1R-B404
	ACAAAGCAGCCAGCGCGCGCUUGACCCGGAGAGUAGCACA

	OC1R-B463
	CAUCCAUGCGCGCGCAGGGGUUAAGCGAGGGUCCUCCAUG

	OC1R-B497
	CUCCGCGCGCGCACUUACCAUCUCUUCGUAAGGAAGUCGA

	OC1R-B606
	AACCUGCAUUAGGCGCGCGCGCGUAGUUGGCACAGCUGUG

	OC1R-B690
	AGCCAGCAGAAUGCCAACCAACGUAGCCGAGGCGCGCGCA

	OC1R-B875
	CUGCUCUCCGGGCGCGCGCACCAACCUCUAGGCAGCUUGG

	OC1R-B952
	GGCAGGGUAAUCUGGGCUGCGCGCGCACCUACAAUGGCUA

	OC1R-B973
	GUGCAAGUUAUGAGAUUGGACGCACCGCGCGCGCAGCCUU

	OC1R-B986
	UAAAGUUGGGUUCGGGGGCGCGCGCACUUCAUCACGACUA

	OC1R-B1115
	UUUCACGCUUCCUGCGCGCGCUAGUGGCAACUCUACCUCC

Any sequences containing the corresponding deoxyribonucleotide motif
SEQ ID NO 244:

5′-GCGCGCGC-3′

are also expected to bind to teeth and are included as embodiments of the present invention.

Example 5. Analysis of Sequences Similarity

Alignment of SEQ ID NO 1 to SEQ ID NO 111 was performed using the software Align X, a component of Vector NTI Advanced 11.5.4 by Themo Fisher Scientific. Several groups of sequences have at least 90%, at least 70%, or at least 50% nucleotide sequence identity as illustrated in the alignments of FIGS. 12, 13, and 14. In these alignments, only the central variable region of the aptamers is included for simplicity. Thus, oligonucleotides with at least 50%, at least 70%, or at least 90% nucleotide sequence identity to sequences selected from the group consisting of SEQ ID NO 1 to SEQ ID NO 111 are included as embodiments of the current invention. FIG. 12 shows the alignment of exemplary sequences with at least 90% nucleotide sequence identity that were identified during the selection process. FIG. 13 shows the alignment of exemplary sequences with at least 70% nucleotide sequence identity that were identified during the selection process. FIG. 14 shows the alignment of exemplary sequences with at least 50% nucleotide sequence identity that were identified during the selection process.

Example 7. DNA Aptamers Binding

Selected DNA aptamers (OC1D-B1/OC1D-A2, OC1D-B9, and OC1D-B25/OC1D-A9) were chemically synthesized with a FAM fluorophore on the 5′end (Eurofins). An aliquot of 250 μL of 1 μM DNA aptamer in 1× binding buffer (10 mM cacodylate buffer, 120 mM NaCl, 5 mM KCl, 50 μM SnF₂, and 0.322% toothpaste; pH 7.2) was placed in the depression of a microscope slide (concavity slides, 3.2 mm thick; United Scientific). Separately, a clean unerupted third molar tooth was washed with water, dried, and coated with human saliva collected fresh from several individuals. The tooth was then placed into the depression of the slide containing the DNA aptamer and incubated for 20 minutes at room temperature. The amount of aptamer bound was determined by measuring the fluorescence remaining in the solution after the tooth was removed (see FIG. 15). The tooth was removed from the slide and washed several times with 250 μL of neutral binding buffer. The fluorescence of each wash solution was measured (see FIG. 16). Bound aptamers were recovered by washing the teeth with two aliquots of 250 mM NaOH. The fluorescence of each elution solution was also measured (see FIG. 17). Not all the aptamer incubated with the teeth was recovered probably due to very strong binding or adsorption inside the teeth.
Given that we have shown that the DNA version of aptamers OC1R-B1/OC1R-A2, OC1R-B9, and OC1R-B25/OC1R-A9 also bind effectively to teeth, it stands to reason that the conclusions arrived at within this example would apply to the DNA versions of the remaining selected aptamers (SEQ ID NO: 112 to SEQ ID NO: 222), included herein as part of the invention and listed in Table 3.

Example 8. Truncation of Aptamers

Starting from the predicted secondary structure of the selected aptamers (OC1D-B1, OC1D-B9, and OC1D-A9), smaller oligonucleotides comprising some of the secondary structure elements were designed. Consideration of consensus motifs within these predicted structures was included in the design of the truncated aptamers (FIGS. 5 to 10). The truncated aptamers all contained highly selected motif sequences that were involved in stem/loop structures within the original aptamers. These selected structures were conserved in the truncated aptamers.
For instance, aptamers OC1D-B1.1, OC1D-B1.2, and OC1D-B1.3 were derived from aptamer OC1D-B1 (see FIGS. 18A-18D). OC1D-B1.1 comprises completely the bent stem/loop structure of the structure, OC1D-B1.2 comprises just the top of the bent stem/loop structure, while OC1D-B1.3 comprises the tight stem/loop structure. Aptamers OC1D-B9.1 and OC1D-B9.2 were derived from aptamer OC1D-B9 (see FIGS. 19A-19C) and correspond to its two-bottom stem/loop substructures. Aptamer OC1D-A9.1 was derived from aptamer OC1D-A9 (see FIGS. 20A and 20B) with a view to maintain the conserved motif element in a minimal aptamer.
FIGS. 21A-21C illustrate the binding results for each of these truncated aptamers to teeth. These binding assays were performed and analyzed in a manner identical to that described previously for the full-length aptamers (see Example 7). For aptamers from OC1D-B1, the truncated aptamer containing the entire bent stem/loop structure (OC1D-B1.1) performed better on teeth compared to the other two. This provides confirmation that the conserved motif identified in the RNA aptamer is conserved and key to the function of this aptamer as well. For aptamers from OC1D-B9, only the truncated aptamer OC1D-B9.2 containing the bottom bent stem/loop structure binds well on teeth. This corresponds well to the higher level of statistical significance associated with the conserved motif within OC1D-B9.2 compared to the conserved motif within OC1D-B9.1. Finally, truncated aptamer OC1D-A9.1 has a higher binding affinity than the parent aptamer, but not as high as other truncated aptamers. The list of sequences of truncated aptamers is included in TABLE 4.

TABLE 2

List of top sequences from selection experiments
A and B. All the pyrimidine nucleotides are fluorinated
at the 2′ position of the pentose group.

			Copy
SEQ ID NO	Name	Total Sequence	Number

1	OC1R-B1	GGGAAGAGAAGGACAUAUGAUUCAUGUGAGAUGA	16160
	or OC1R-	UGUGUGUUCCUAGUUUUAUCUUGCUCUUUGACUA
	A2	GUACAUGACCACUU

2	OC1R-B2	GGGAAGAGAAGGACAUAUGAUUAGGCUAACUGUU	7945
	or OC1R-	CAGGGAUUUGAUAUGCAUGAGGAGCACUUGACUA
	A1	GUACAUGACCACUU

3	OC1R-B3	GGGAAGAGAAGGACAUAUGAUCCGCUCUAAAGUA	7939
	or OC1R-	CCAACCGCGGGAGCUAAAUGCAAGCCGUUGACUAG
	A19	UACAUGACCACUU

4	OC1R-B4	GGGAAGAGAAGGACAUAUGAUUGUGUCAGGCUCU	4041
		AGAGUCUAGACGGCCGGGGUCCCGGAUUUGACUA
		GUACAUGACCACUU

5	OC1R-B5	GGGAAGAGAAGGACAUAUGAUCCUUAUGUCUAGC	2867
		GGCCUUACGCGAUUAGUGGCGUUUUGUUUGACUA
		GUACAUGACCACUU

6	OC1R-B6	GGGAAGAGAAGGACAUAUGAUCUUUAUGUAUUAU	1841
		CAGUCAUACCGGACGCAGCCCGCUGGAUUGACUAG
		UACAUGACCACUU

7	OC1R-B7	GGGAAGAGAAGGACAUAUGAUUGUGUUAUUACAC	1464
	or OC1R-	UUCGUGAUUUUCCUUGCUUUUCUAUUUUUGACUA
	A3	GUACAUGACCACUU

8	OC1R-B8	GGGAAGAGAAGGACAUAUGAUCCAACAUCUAAAG	1373
		UACUGGUCGCCUAGGGAGACUGUUCGGUUGACUA
		GUACAUGACCACUU

9	OC1R-B9	GGGAAGAGAAGGACAUAUGAUGCUAUAUUCGCAA	851
		AAGCAGGCUGAGUGCGGCAGGCGCGUGUUGACUA
		GUACAUGACCACUU

10	OC1R-	GGGAAGAGAAGGACAUAUGAUUCAUUCAUUCGCA	759
	B10	ACACAAUUGUAUUCGCAUCUGCGAUUUUUGACUA
		GUACAUGACCACUU

11	OC1R-	GGGAAGAGAAGGACAUAUGAUCUUUCUCUUUUCU	561
	B11 or	AAUAUUUAAUUUAUUGGGUACCAAUUUUUGACUA
	OC1R-	GUACAUGACCACUU
	A11

12	OC1R-	GGGAAGAGAAGGACAUAUGAUCUUUGUUUCGCAU	425
	B12 or	ACGUUUUCUUUUUCUCUCUUCUUAUUUUUGACUA
	OC1R-A7	GUACAUGACCACUU

13	OC1R-	GGGAAGAGAAGGACAUAUGAUUAUUCUGUUCUUC	402
	B13 or	AAAAAUCUUUUAGCGUAUACGCUAUUUUUGACUA
	OC1R-A5	GUACAUGACCACUU

14	OC1R-	GGGAAGAGAAGGACAUAUGAUUUCCUUAUGUUCG	396
	B14	GUCAACAGGGACUGCUGCAGCACCGGCUUGACUAG
		UACAUGACCACUU

15	OC1R-	GGGAAGAGAAGGACAUAUGAUUAAGCGCACUCAA	371
	B15	CAGGGUCUAUGAUCCGCGCCGAUCAUGUUGACUAG
		UACAUGACCACUU

16	OC1R-	GGGAAGAGAAGGACAUAUGAUCCGCUUUCCAUUG	357
	B16 or	AGAUUAUAAGCUGUUAGAGACUUAUUUUUGACUA
	OC1R-	GUACAUGACCACUU
	A15

17	OC1R-	GGGAAGAGAAGGACAUAUGAUUUUCGAAACGUUU	353
	B17 or	CUUUCAAGUUCUUAAUCAUUCCCAUUUUUGACUA
	OC1R-A8	GUACAUGACCACUU

18	OC1R-	GGGAAGAGAAGGACAUAUGAUCAUUAGAUGCGCA	297
	B18	GUUCGAAGCCGGUACAGCUGGCGCGCGUUGACUAG
		UACAUGACCACUU

19	OC1R-	GGGAAGAGAAGGACAUAUGAUAAAGAAUAACCUU	290
	B19	AAAAUAACACCACCGCCUCACAGCAUAUUGACUAG
		UACAUGACCACUU

20	OC1R-	GGGAAGAGAAGGACAUAUGAUAAAUUGAUCUAUU	282
	B20 or	CUUUUCGGUGCUAUUUAUCUUCCAUUUUUGACUA
	OC1R-A6	GUACAUGACCACUU

21	OC1R-	GGGAAGAGAAGGACAUAUGAUCUACUCGCGCGGC	282
	B21	GGACAAAAGCGCAACCCAGCACCCAUGUUGACUAG
		UACAUGACCACUU

22	OC1R-	GGGAAGAGAAGGACAUAUGAUUCUUAGUUUGUAA	255
	B22 or	UUACUUUUCCUUCCUUUUAUUCUAUUUUUGACUA
	OC1R-	GUACAUGACCACUU
	A10

23	OC1R-	GGGAAGAGAAGGACAUAUGAUAACCCGCGCAGAC	227
	B23	UUACAAGCGCGCAAAAAAAGGGUACGUUUGACUA
		GUACAUGACCACUU

24	OC1R-	GGGAAGAGAAGGACAUAUGAUAUUCCUUUAUGCC	209
	B24 or	GCAUCAUUUUAUUGUUUAUGACAAUUUUUGACUA
	OC1R-	GUACAUGACCACUU
	A23

25	OC1R-	GGGAAGAGAAGGACAUAUGAUAUUUCGUACUACU	209
	B25 or	UUUCUUCCAAGCUUCAAUCGCCCAUUUUUGACUAG
	OC1R-A9	UACAUGACCACUU

26	OC1R-	GGGAAGAGAAGGACAUAUGAUUCACUCAUUCGCA	198
	B26 or	ACACAAUUGUAUUCGCAUCUGCGAUUUUUGACUA
	OC1R-	GUACAUGACCACUU
	A24

27	OC1R-	GGGAAGAGAAGGACAUAUGAUAUUAUUUCCACAG	190
	B27 or	UUCCUUUAUCCACACAUCUUCUCAUUUUUGACUAG
	OC1R-	UACAUGACCACUU
	A12

28	OC1R-	GGGAAGAGAAGGACAUAUGAUAAACUCGUUAUCU	187
	B28	AUUCGUUUAUUUGCAUCUCUUUCAUUUUUGACUA
		GUACAUGACCACUU

29	OC1R-	GGGAAGAGAAGGACAUAUGAUCCAACCUCUAAAG	185
	B29	UACUGGUCGCCUAGGGAGACUGUUCGGUUGACUA
		GUACAUGACCACUU

30	OC1R-	GGGAAGAGAAGGACAUAUGAUUUCCUUUUUGCUA	179
	B30	UUUCCGUUAAUGUAAACUCUCCUAUUUUUGACUA
	OC1R-	GUACAUGACCACUU
	A13

31	OC1R-	GGGAAGAGAAGGACAUAUGAUCCUUAUGGCCUAG	167
	B31	UAGGGAUCCGGGCGCCGACCAGCGCGAUUGACUAG
		UACAUGACCACUU

32	OC1R-	GGGAAGAGAAGGACAUAUGAUCGUCUGUCUUCUU	153
	B32	CGAAUACGUUUUGGGCUAAGCCCAUUUUUGACUA
	OC1R-	GUACAUGACCACUU
	A18

33	OC1R-	GGGAAGAGAAGGACAUAUGAUUCAACCAAACUGC	143
	B33	CGACGACCGAGGUAUGUCCUUAUGUACUUGACUA
		GUACAUGACCACUU

34	OC1R-	GGGAAGAGAAGGACAUAUGAUUACGGGUCUGAGC	142
	B34	AAAAGCGAAGGAAGCAGGCGCAGGGAUUUGACUA
		GUACAUGACCACUU

35	OC1R-	GGGAAGAGAAGGACAUAUGAUUCUCUCAUUCGCA	134
	B35 or	ACACAAUUGUAUUCGCAUCUGCGAUUUUUGACUA
	OC1R-A4	GUACAUGACCACUU

36	OC1R-	GGGAAGAGAAGGACAUAUGAUGCUCUAAAGUACU	127
	B36	AAGCGUUUGCGCCGAUGCCCGGACCGCUUGACUAG
		UACAUGACCACUU

37	OC1R-	GGGAAGAGAAGGACAUAUGAUACUUCAUUAAUGU	126
	B37	GAGGCCGUCAGGGGGCAACCUUCGAGCUUGACUAG
		UACAUGACCACUU

38	OC1R-	GGGAAGAGAAGGACAUAUGAUUCCUUAUUCUUGU	126
	B38	UACUACUUUCUUUUCCUAUUUUUUUCUUUGACUA
		GUACAUGACCACUU

39	OC1R-	GGGAAGAGAAGGACAUAUGAUCGUUAUUUUCAUU	125
	B39 or	UUCUUGUUCCCCAUAUGCCCAGGCGCAUUGACUAG
	OC1R-	UACAUGACCACUU
	A14

40	OC1R-	GGGAAGAGAAGGACAUAUGAUACCAGCGGCGUAG	120
	B40	AAACGUACAGCUCGCCUGUAACGCCUGUUGACUAG
		UACAUGACCACUU

41	OC1R-	GGGAAGAGAAGGACAUAUGAUCGAUAUGGGUGCG	107
	B41	GGAAUGUACGUUCACCGAAUAUGCUCCUUGACUA
		GUACAUGACCACUU

42	OC1R-	GGGAAGAGAAGGACAUAUGAUUAACAGUGCGUAG	95
	B42	UCAUAUCGAAUGUUUAUCUUCCUAUUUUUGACUA
		GUACAUGACCACUU

43	OC1R-	GGGAAGAGAAGGACAUAUGAUCAGACUCUCGCCC	94
	B43	AAUUCGCAAGGCGUUGCAUUGCGAUUUUUGACUA
		GUACAUGACCACUU

44	OC1R-	GGGAAGAGAAGGACAUAUGAUUUCCAACUCUCCA	88
	B44	CGAGAGCAUGGGUCGAAUGACUCAUUUUUGACUA
		GUACAUGACCACUU

45	OC1R-	GGGAAGAGAAGGACAUAUGAUGCAUCGCGCGUCA	86
	B45	CUCAACUCGUGAUUACCGAGGGCGCCGUUGACUAG
		UACAUGACCACUU

46	OC1R-	GGGAAGAGAAGGACAUAUGAUCUGAAUCUUUCCG	82
	B46	CAGCCCUGUCCUUUUAAAGACAGGUUUUUGACUA
		GUACAUGACCACUU

47	OC1R-	GGGAAGAGAAGGACAUAUGAUUUUGUUACUUACU	70
	B47	UCGUCUAUCUUCUGUUGCACACAGUUUUUGACUA
		GUACAUGACCACUU

48	OC1R-	GGGAAGAGAAGGACAUAUGAUUCAAAUCUUCAGC	69
	B48	GAUAAUGGCACAAUUUCCGCGCCAUUUUUGACUA
		GUACAUGACCACUU

49	OC1R-	GGGAAGAGAAGGACAUAUGAUUUAUGUGAGAUGA	67
	B49	UGUGUGUUCCUAGUUUUAUCUUGCUCUUUGACUA
		GUACAUGACCACUU

50	OC1R-	GGGAAGAGAAGGACAUAUGAUCCACUUUUCCAUU	62
	B50	AACUGUUGCGGGCAAGUAGCACCGUUUUUGACUA
		GUACAUGACCACUU

51	OC1R-	GGGAAGAGAAGGACAUAUGAUAGAGAAGACCAUU	59
	B51	CGGAAAGAGCUGCGUGUCCUUAUGUACUUGACUA
		GUACAUGACCACUU

52	OC1R-	GGGAAGAGAAGGACAUAUGAUUCUUAUGUAGCAA	58
	B52	GCAAAAUGUGCCGCCGAGCCGACGCCAUUGACUAG
		UACAUGACCACUU

53	OC1R-	GGGAAGAGAAGGACAUAUGAUAAGCGCAUAAUAA	56
	B53	GCCAGCCAGUUCUUGGCGCGCGGGGUAUUGACUAG
		UACAUGACCACUU

54	OC1R-	GGGAAGAGAAGGACAUAUGAUUAGUCCGCAUUUC	56
	B54	UAUUUUCUAUAUGGCUUACUGCCAUUUUUGACUA
		GUACAUGACCACUU

55	OC1R-	GGGAAGAGAAGGACAUAUGAUAUAAAGAACACGC	44
	B55	AAAACCACCCGGACACCCGGUGCCGUGUUGACUAG
		UACAUGACCACUU

56	OC1R-	GGGAAGAGAAGGACAUAUGAUACACAGGCGGUGG	42
	B56	AGCCGAAGGGCACCGGGACAAACCGACUUGACUAG
		UACAUGACCACUU

57	OC1R-	GGGAAGAGAAGGACAUAUGAUAGUUCCGGCGCAG	39
	B57	CAGCGUCCUCACGUUUUACGUGCCCCAUUGACUAG
		UACAUGACCACUU

58	OC1R-	GGGAAGAGAAGGACAUAUGAUGACCGUCGCGAUC	39
	B58	GUUUAUAAUGUUCUGGAUCUUUCAUUUUUGACUA
		GUACAUGACCACUU

59	OC1R-	GGGAAGAGAAGGACAUAUGAUAAGUGGGGCCCCG	37
	B59	ACGACUUUUCCUUCCUCUCUUCCGGCAUUGACUAG
		UACAUGACCACUU

60	OC1R-	GGGAAGAGAAGGACAUAUGAUAUCAACAUACCAA	37
	B60	AAUGUCAUUUCCAAUCUUUUCCCAUUUUUGACUA
		GUACAUGACCACUU

61	OC1R-	GGGAAGAGAAGGACAUAUGAUAGCGAACAAACAA	36
	B61	GGGUGCCCAGGCCCCCUUCGCACAUCGUUGACUAG
		UACAUGACCACUU

62	OC1R-	GGGAAGAGAAGGACAUAUGAUCCUCUGUAACGCA	35
	B62	AAGUCAAGUCGCGCAAGGCCGCCCGCGUUGACUAG
		UACAUGACCACUU

63	OC1R-	GGGAAGAGAAGGACAUAUGAUCUUCAUCUGCGAU	35
	B63	UACGGUACACUUUAGUGUAUCGUUUUUUUGACUA
		GUACAUGACCACUU

64	OC1R-	GGGAAGAGAAGGACAUAUGAUGCCUAUGUGCUAG	35
	B64	AUGCAGCAGCAACCGCCGGCGACUGGAUUGACUAG
		UACAUGACCACUU

65	OC1R-	GGGAAGAGAAGGACAUAUGAUCCGCGCCCUAACCU	33
	B65	UCUGACCAAGCUUCCCUGGCACUUGGUUGACUAGU
		ACAUGACCACUU

66	OC1R-	GGGAAGAGAAGGACAUAUGAUCCUUAUGUAUUAU	33
	B66	CAGUCAUACCGGACGCAGCCCGCUGGAUUGACUAG
		UACAUGACCACUU

67	OC1R-	GGGAAGAGAAGGACAUAUGAUCUAAUCUAUACUG	33
	B67	GCUGCUAACGCUUUUUCUUUUCCAUUUUUGACUA
		GUACAUGACCACUU

68	OC1R-	GGGAAGAGAAGGACAUAUGAUCAGUUUACGCGGA	32
	B68	GUCGUUUGUGUCCAUUUCUUCUCAUUUUUGACUA
		GUACAUGACCACUU

69	OC1R-	GGGAAGAGAAGGACAUAUGAUUCACGUGAGAUGA	32
	B69	UGUGUGUUCCUAGUUUUAUCUUGCUCUUUGACUA
		GUACAUGACCACUU

70	OC1R-	GGGAAGAGAAGGACAUAUGAUUCCUUGUGUACCG	32
	B70	CUCCGAAUGUGCUCCAGCGCGCCUCGGUUGACUAG
		UACAUGACCACUU

71	OC1R-	GGGAAGAGAAGGACAUAUGAUAAGCCGGCCCGGG	31
	B71	AACAUGUCACGCGCGCGCGCAAAGUAGUUGACUAG
		UACAUGACCACUU

72	OC1R-	GGGAAGAGAAGGACAUAUGAUCCUGGAUUUCCGA	31
	B72	AAUUAGAGUGCCGUUUCGUUACGGUUUUUGACUA
		GUACAUGACCACUU

73	OC1R-	GGGAAGAGAAGGACAUAUGAUCGUGUCAUCCGCA	31
	B73	CAAGGAGGCCUGCAUGGCAGGGACACGUUGACUA
		GUACAUGACCACUU

74	OC1R-	GGGAAGAGAAGGACAUAUGAUGAGUAGACUUUUU	31
	B74	GUAUCAUUUUUUUAUCGUAAGAUAUUUUUGACUA
		GUACAUGACCACUU

75	OC1R-	GGGAAGAGAAGGACAUAUGAUCCAUGUGAGAUGA	30
	B75	UGUGUGUUCCUAGUUUUAUCUUGCUCUUUGACUA
		GUACAUGACCACUU

76	OC1R-	GGGAAGAGAAGGACAUAUGAUCUUUGCUCUAGAG	29
	B76	UGUAGUCUAUGAGGGACAAGGUAGCCAUUGACUA
		GUACAUGACCACUU

77	OC1R-	GGGAAGAGAAGGACAUAUGAUGUUGGUUUUCUUU	29
	B77	CUCUUUCUUUUCUUUCUCUUUCUAUUUUUGACUA
		GUACAUGACCACUU

78	OC1R-	GGGAAGAGAAGGACAUAUGAUCAAUCGGGCGGGG	28
	B78	GUAAGAGGCGUGCGCAGCGUGGAGGUGUUGACUA
		GUACAUGACCACUU

79	OC1R-	GGGAAGAGAAGGACAUAUGAUCACCGUGGUGCGC	27
	B79	AAAGCCGCAACGAGAACUGCGGAAUCGUUGACUA
		GUACAUGACCACUU

80	OC1R-	GGGAAGAGAAGGACAUAUGAUUGCUUUAAGUCUU	26
	B80	UUUAUCAUUUUGUUUCCUUCAUUUUUUUUGACUA
		GUACAUGACCACUU

81	OC1R-	GGGAAGAGAAGGACAUAUGAUCGACUAGUUAUAC	25
	B81	UGCAAAGGCUAUAAGCGCGAGCGCGCGUUGACUA
		GUACAUGACCACUU

82	OC1R-	GGGAAGAGAAGGACAUAUGAUGAGUAAUAGAUGG	25
	B82	CGUACACAAAUCGGAUACGACGAGCGCUUGACUAG
		UACAUGACCACUU

83	OC1R-	GGGAAGAGAAGGACAUAUGAUUUUCGCUUCAAGA	25
	B83	UUCCCAACGCCUUGUAAGUCAAGGUUUUUGACUA
		GUACAUGACCACUU

84	OC1R-	GGGAAGAGAAGGACAUAUGAUGUGUGAGAUGAGC	24
	B84	CCCUGGACCAGACGCACGCUCGCACUGUUGACUAG
		UACAUGACCACUU

85	OC1R-	GGGAAGAGAAGGACAUAUGAUCAGGAUGCGGCGC	23
	B85	CGGUAAUUGACUUCCCCCUACGUAGGAUUGACUAG
		UACAUGACCACUU

86	OC1R-	GGGAAGAGAAGGACAUAUGAUCAGGGACCCGGCC	22
	B86	GGUGCAUCUCCUUCUUUAGCGUACGCCUUGACUAG
		UACAUGACCACUU

87	OC1R-	GGGAAGAGAAGGACAUAUGAUCUGCUCUAAAGUA	22
	B87	CCAACCGCGGGAGCUAAAUGCAAGCCGUUGACUAG
		UACAUGACCACUU

88	OC1R-	GGGAAGAGAAGGACAUAUGAUGAUUGCCAUGCAU	22
	B88	UAGGGGGGGACGCGCGCGAAAGGGAGAUUGACUA
		GUACAUGACCACUU

89	OC1R-	GGGAAGAGAAGGACAUAUGAUUCGCUCUAAAGUA	22
	B89	CCAACCGCGGGAGCUAAAUGCAAGCCGUUGACUAG
		UACAUGACCACUU

90	OC1R-	GGGAAGAGAAGGACAUAUGAUAAAAAACCGGGGU	21
	B90	UCUUAAUUUUCAUUGUUCGUCGUACUUUUGACUA
		GUACAUGACCACUU

91	OC1R-	GGGAAGAGAAGGACAUAUGAUAACCCAUUGGUGA	21
	B91	AUCGCAACCACAGCCAGCCCGGCGCGAUUGACUAG
		UACAUGACCACUU

92	OC1R-	GGGAAGAGAAGGACAUAUGAUCGAAGUGAGGGGA	21
	B92	UCGCGCGGGGUGCACCUAAAUAUGGGAUUGACUA
		GUACAUGACCACUU

93	OC1R-	GGGAAGAGAAGGACAUAUGAUAGCCUUAUGUACU	20
	B93	AUAGAAGUCAGCUAUCCGCCGCACAAUUUGACUAG
		UACAUGACCACUU

94	OC1R-	GGGAAGAGAAGGACAUAUGAUCGUUGUUUUUCCC	20
	B94	AAAGCUCGUUAGCAUUCAUUCCUAUUUUUGACUA
		GUACAUGACCACUU

95	OC1R-	GGGAAGAGAAGGACAUAUGAUGAUCAUCAGCGGA	20
	B95	AAGCACGAAACGCCACGGGCCGCGGCAUUGACUAG
		UACAUGACCACUU

96	OC1R-	GGGAAGAGAAGGACAUAUGAUUCCUUCCUAUUGA	20
	B96	CAAUGCGCCCGGGCCUCUUCAAUUGUAUUGACUAG
		UACAUGACCACUU

97	OC1R-	GGGAAGAGAAGGACAUAUGAUAGUUGCCGCGCGG	18
	B97	CGCAAGAUUGGAGAGUCCCGGGCUGUAUUGACUA
		GUACAUGACCACUU

98	OC1R-	GGGAAGAGAAGGACAUAUGAUCAUAAGUUCGUUC	18
	B98	AUUCCGUUAACACGCGUAUGGCGUUUUUUGACUA
		GUACAUGACCACUU

99	OC1R-	GGGAAGAGAAGGACAUAUGAUCCUUUGUCUCCAA	18
	B99	AUCUUAGGACUGAAUGAGUGCCUAUUUUUGACUA
		GUACAUGACCACUU

100	OC1R-	GGGAAGAGAAGGACAUAUGAUCUUCUUUGAGAAU	18
	B100	UCUCUUUUUACAAUUCCGGCGCCGUGAUUGACUAG
		UACAUGACCACUU

101	OC1R-	GGGAAGAGAAGGACAUAUGAUUAGGCUAACUGUU	3130
	A16	UAGGGAUUUGAUAUGCAUGAGGAGCACUUGACUA
		GUACAUGACCACUU

102	OC1R-	GGGAAGAGAAGGACAUAUGAUCGUCUGUCUUCUU	2970
	A17	CGAAUACGUUUUGGGCUAAGCCCAUUUUUGACUA
		GUACAUGACCACUU

103	OC1R-	GGGAAGAGAAGGACAUAUGAUUAGGCUAACUGCU	2753
	A20	CAGGGAUUUGAUAUGCAUGAGGAGCACUUGACUA
		GUACAUGACCACUU

104	OC1R-	GGGAAGAGAAGGACAUAUGAUUAGGCUAACUGUU	2642
	A21	CAGGGACUUGAUAUGCAUGAGGAGCACUUGACUA
		GUACAUGACCACUU

105	OC1R-	GGGAAGAGAAGGACAUAUGAUUAGGCUCACUGUU	2627
	A22	CAGGGAUUUGAUAUGCAUGAGGAGCACUUGACUA
		GUACAUGACCACUU

106	OC1R-	GGGAAGAGAAGGACAUAUGAUUAGGCUAACUGUU	2250
	A25	CAGGGAUUUGAUAUGCAUGGGGAGCACUUGACUA
		GUACAUGACCACUU

107	OC1R-	GGGAAGAGAAGGACAUAUGAUUUCUUCCUAUUGA	2195
	A26	CGAUGCGCCCGGGCCUCUUCAAUUGUAUUGACUAG
		UACAUGACCACUU

108	OC1R-	GGGAAGAGAAGGACAUAUGAUUAGGCUAACUGUU	2156
	A27	CGGGGAUUUGAUAUGCAUGAGGAGCACUUGACUA
		GUACAUGACCACUU

109	OC1R-	GGGAAGAGAAGGACAUAUGAUUAGGCUAACUGUU	2074
	A28	CAGGGAUUUGAUAUGCACGAGGAGCACUUGACUA
		GUACAUGACCACUU

110	OC1R-	GGGAAGAGAAGGACAUAUGAUUAGGUUAACUGUU	2042
	A29	CAGGGAUUUGAUAUGCAUGAGGAGCACUUGACUA
		GUACAUGACCACUU

111	OC1R-	GGGAAGAGAAGGACAUAUGAUUAGGCUAACUGUU	2031
	A30	CAGGGAUUUGAUGUGCAUGAGGAGCACUUGACUA
		GUACAUGACCACUU

TABLE 3

List of deoxyribonucleotides aptamers based on the
top sequences from selection experiments A and B.

SEQ ID
NO	Name	Total Sequence

112	OC1D-	GGGAAGAGAAGGACATATGATTCATGTGAGATGATGTGTGTTCCTAG
	B1 or	TTTTATCTTGCTCTTTGACTAGTACATGACCACTT
	OC1D-
	A2

113	OC1D-	GGGAAGAGAAGGACATATGATTAGGCTAACTGTTCAGGGATTTGATA
	B2 or	TGCATGAGGAGCACTTGACTAGTACATGACCACTT
	OC1D-
	A1

114	OC1D-	GGGAAGAGAAGGACATATGATCCGCTCTAAAGTACCAACCGCGGGA
	B3 or	GCTAAATGCAAGCCGTTGACTAGTACATGACCACTT
	OC1D-
	A19

115	OC1D-	GGGAAGAGAAGGACATATGATTGTGTCAGGCTCTAGAGTCTAGACGG
	B4	CCGGGGTCCCGGATTTGACTAGTACATGACCACTT

116	OC1D-	GGGAAGAGAAGGACATATGATCCTTATGTCTAGCGGCCTTACGCGAT
	B5	TAGTGGCGTTTTGTTTGACTAGTACATGACCACTT

117	OC1D-	GGGAAGAGAAGGACATATGATCTTTATGTATTATCAGTCATACCGGA
	B6	CGCAGCCCGCTGGATTGACTAGTACATGACCACTT

118	OC1D-	GGGAAGAGAAGGACATATGATTGTGTTATTACACTTCGTGATTTTCCT
	B7 or	TGCTTTTCTATTTTTGACTAGTACATGACCACTT
	OC1D-
	A3

119	OC1D-	GGGAAGAGAAGGACATATGATCCAACATCTAAAGTACTGGTCGCCTA
	B8	GGGAGACTGTTCGGTTGACTAGTACATGACCACTT

120	OC1D-	GGGAAGAGAAGGACATATGATGCTATATTCGCAAAAGCAGGCTGAG
	B9	TGCGGCAGGCGCGTGTTGACTAGTACATGACCACTT

121	OC1D-	GGGAAGAGAAGGACATATGATTCATTCATTCGCAACACAATTGTATT
	B10	CGCATCTGCGATTTTTGACTAGTACATGACCACTT

122	OC1D-	GGGAAGAGAAGGACATATGATCTTTCTCTTTTCTAATATTTAATTTAT
	B11 or	TGGGTACCAATTTTTGACTAGTACATGACCACTT
	OC1D-
	A11

123	OC1D-	GGGAAGAGAAGGACATATGATCTTTGTTTCGCATACGTTTTCTTTTTC
	B12 or	TCTCTTCTTATTTTTGACTAGTACATGACCACTT
	OC1D-
	A7

124	OC1D-	GGGAAGAGAAGGACATATGATTATTCTGTTCTTCAAAAATCTTTTAG
	B13 or	CGTATACGCTATTTTTGACTAGTACATGACCACTT
	OC1D-
	A5

125	OC1D-	GGGAAGAGAAGGACATATGATTTCCTTATGTTCGGTCAACAGGGACT
	B14	GCTGCAGCACCGGCTTGACTAGTACATGACCACTT

126	OC1D-	GGGAAGAGAAGGACATATGATTAAGCGCACTCAACAGGGTCTATGA
	B15	TCCGCGCCGATCATGTTGACTAGTACATGACCACTT

127	OC1D-	GGGAAGAGAAGGACATATGATCCGCTTTCCATTGAGATTATAAGCTG
	B16 or	TTAGAGACTTATTTTTGACTAGTACATGACCACTT
	OC1D-
	A15

128	OC1D-	GGGAAGAGAAGGACATATGATTTTCGAAACGTTTCTTTCAAGTTCTT
	B17 or	AATCATTCCCATTTTTGACTAGTACATGACCACTT
	OC1D-
	A8

129	OC1D-	GGGAAGAGAAGGACATATGATCATTAGATGCGCAGTTCGAAGCCGG
	B18	TACAGCTGGCGCGCGTTGACTAGTACATGACCACTT

130	OC1D-	GGGAAGAGAAGGACATATGATAAAGAATAACCTTAAAATAACACCA
	B19	CCGCCTCACAGCATATTGACTAGTACATGACCACTT

131	OC1D-	GGGAAGAGAAGGACATATGATAAATTGATCTATTCTTTTCGGTGCTA
	B20 or	TTTATCTTCCATTTTTGACTAGTACATGACCACTT
	OC1D-
	A6

132	OC1D-	GGGAAGAGAAGGACATATGATCTACTCGCGCGGCGGACAAAAGCGC
	B21	AACCCAGCACCCATGTTGACTAGTACATGACCACTT

133	OC1D-	GGGAAGAGAAGGACATATGATTCTTAGTTTGTAATTACTTTTCCTTCC
	B22 or	TTTTATTCTATTTTTGACTAGTACATGACCACTT
	OC1D-
	A10

134	OC1D-	GGGAAGAGAAGGACATATGATAACCCGCGCAGACTTACAAGCGCGC
	B23	AAAAAAAGGGTACGTTTGACTAGTACATGACCACTT

135	OC1D-	GGGAAGAGAAGGACATATGATATTCCTTTATGCCGCATCATTTTATTG
	B24 or	TTTATGACAATTTTTGACTAGTACATGACCACTT
	OC1D-
	A23

136	OC1D-	GGGAAGAGAAGGACATATGATATTTCGTACTACTTTTCTTCCAAGCTT
	B25 or	CAATCGCCCATTTTTGACTAGTACATGACCACTT
	OC1D-
	A9

137	OC1D-	GGGAAGAGAAGGACATATGATTCACTCATTCGCAACACAATTGTATT
	B26 or	CGCATCTGCGATTTTTGACTAGTACATGACCACTT
	OC1D-
	A24

138	OC1D-	GGGAAGAGAAGGACATATGATATTATTTCCACAGTTCCTTTATCCAC
	B27 or	ACATCTTCTCATTTTTGACTAGTACATGACCACTT
	OC1D-
	A12

139	OC1D-	GGGAAGAGAAGGACATATGATAAACTCGTTATCTATTCGTTTATTTG
	B28	CATCTCTTTCATTTTTGACTAGTACATGACCACTT

140	OC1D-	GGGAAGAGAAGGACATATGATCCAACCTCTAAAGTACTGGTCGCCTA
	B29	GGGAGACTGTTCGGTTGACTAGTACATGACCACTT

141	OC1D-	GGGAAGAGAAGGACATATGATTTCCTTTTTGCTATTTCCGTTAATGTA
	B30	AACTCTCCTATTTTTGACTAGTACATGACCACTT
	OC1D-
	A13

142	OC1D-	GGGAAGAGAAGGACATATGATCCTTATGGCCTAGTAGGGATCCGGGC
	B31	GCCGACCAGCGCGATTGACTAGTACATGACCACTT

143	OC1D-	GGGAAGAGAAGGACATATGATCGTCTGTCTTCTTCGAATACGTTTTG
	B32	GGCTAAGCCCATTTTTGACTAGTACATGACCACTT
	OC1D-
	A18

144	OC1D-	GGGAAGAGAAGGACATATGATTCAACCAAACTGCCGACGACCGAGG
	B33	TATGTCCTTATGTACTTGACTAGTACATGACCACTT

145	OC1D-	GGGAAGAGAAGGACATATGATTACGGGTCTGAGCAAAAGCGAAGGA
	B34	AGCAGGCGCAGGGATTTGACTAGTACATGACCACTT

146	OC1D-	GGGAAGAGAAGGACATATGATTCTCTCATTCGCAACACAATTGTATT
	B35 or	CGCATCTGCGATTTTTGACTAGTACATGACCACTT
	OC1D-
	A4

147	OC1D-	GGGAAGAGAAGGACATATGATGCTCTAAAGTACTAAGCGTTTGCGCC
	B36	GATGCCCGGACCGCTTGACTAGTACATGACCACTT

148	OC1D-	GGGAAGAGAAGGACATATGATACTTCATTAATGTGAGGCCGTCAGGG
	B37	GGCAACCTTCGAGCTTGACTAGTACATGACCACTT

149	OC1D-	GGGAAGAGAAGGACATATGATTCCTTATTCTTGTTACTACTTTCTTTT
	B38	CCTATTTTTTTCTTTGACTAGTACATGACCACTT

150	OC1D-	GGGAAGAGAAGGACATATGATCGTTATTTTCATTTTCTTGTTCCCCAT
	B39 or	ATGCCCAGGCGCATTGACTAGTACATGACCACTT
	OC1D-
	A14

151	OC1D-	GGGAAGAGAAGGACATATGATACCAGCGGCGTAGAAACGTACAGCT
	B40	CGCCTGTAACGCCTGTTGACTAGTACATGACCACTT

152	OC1D-	GGGAAGAGAAGGACATATGATCGATATGGGTGCGGGAATGTACGTT
	B41	CACCGAATATGCTCCTTGACTAGTACATGACCACTT

153	OC1D-	GGGAAGAGAAGGACATATGATTAACAGTGCGTAGTCATATCGAATGT
	B42	TTATCTTCCTATTTTTGACTAGTACATGACCACTT

154	OC1D-	GGGAAGAGAAGGACATATGATCAGACTCTCGCCCAATTCGCAAGGC
	B43	GTTGCATTGCGATTTTTGACTAGTACATGACCACTT

155	OC1D-	GGGAAGAGAAGGACATATGATTTCCAACTCTCCACGAGAGCATGGGT
	B44	CGAATGACTCATTTTTGACTAGTACATGACCACTT

156	OC1D-	GGGAAGAGAAGGACATATGATGCATCGCGCGTCACTCAACTCGTGAT
	B45	TACCGAGGGCGCCGTTGACTAGTACATGACCACTT

157	OC1D-	GGGAAGAGAAGGACATATGATCTGAATCTTTCCGCAGCCCTGTCCTT
	B46	TTAAAGACAGGTTTTTGACTAGTACATGACCACTT

158	OC1D-	GGGAAGAGAAGGACATATGATTTTGTTACTTACTTCGTCTATCTTCTG
	B47	TTGCACACAGTTTTTGACTAGTACATGACCACTT

159	OC1D-	GGGAAGAGAAGGACATATGATTCAAATCTTCAGCGATAATGGCACA
	B48	ATTTCCGCGCCATTTTTGACTAGTACATGACCACTT

160	OC1D-	GGGAAGAGAAGGACATATGATTTATGTGAGATGATGTGTGTTCCTAG
	B49	TTTTATCTTGCTCTTTGACTAGTACATGACCACTT

161	OC1D-	GGGAAGAGAAGGACATATGATCCACTTTTCCATTAACTGTTGCGGGC
	B50	AAGTAGCACCGTTTTTGACTAGTACATGACCACTT

162	OC1D-	GGGAAGAGAAGGACATATGATAGAGAAGACCATTCGGAAAGAGCTG
	B51	CGTGTCCTTATGTACTTGACTAGTACATGACCACTT

163	OC1D-	GGGAAGAGAAGGACATATGATTCTTATGTAGCAAGCAAAATGTGCCG
	B52	CCGAGCCGACGCCATTGACTAGTACATGACCACTT

164	OC1D-	GGGAAGAGAAGGACATATGATAAGCGCATAATAAGCCAGCCAGTTC
	B53	TTGGCGCGCGGGGTATTGACTAGTACATGACCACTT

165	OC1D-	GGGAAGAGAAGGACATATGATTAGTCCGCATTTCTATTTTCTATATG
	B54	GCTTACTGCCATTTTTGACTAGTACATGACCACTT

166	OC1D-	GGGAAGAGAAGGACATATGATATAAAGAACACGCAAAACCACCCGG
	B55	ACACCCGGTGCCGTGTTGACTAGTACATGACCACTT

167	OC1D-	GGGAAGAGAAGGACATATGATACACAGGCGGTGGAGCCGAAGGGCA
	B56	CCGGGACAAACCGACTTGACTAGTACATGACCACTT

168	OC1D-	GGGAAGAGAAGGACATATGATAGTTCCGGCGCAGCAGCGTCCTCAC
	B57	GTTTTACGTGCCCCATTGACTAGTACATGACCACTT

169	OC1D-	GGGAAGAGAAGGACATATGATGACCGTCGCGATCGTTTATAATGTTC
	B58	TGGATCTTTCATTTTTGACTAGTACATGACCACTT

170	OC1D-	GGGAAGAGAAGGACATATGATAAGTGGGGCCCCGACGACTTTTCCTT
	B59	CCTCTCTTCCGGCATTGACTAGTACATGACCACTT

171	OC1D-	GGGAAGAGAAGGACATATGATATCAACATACCAAAATGTCATTTCCA
	B60	ATCTTTTCCCATTTTTGACTAGTACATGACCACTT

172	OC1D-	GGGAAGAGAAGGACATATGATAGCGAACAAACAAGGGTGCCCAGGC
	B61	CCCCTTCGCACATCGTTGACTAGTACATGACCACTT

173	OC1D-	GGGAAGAGAAGGACATATGATCCTCTGTAACGCAAAGTCAAGTCGC
	B62	GCAAGGCCGCCCGCGTTGACTAGTACATGACCACTT

174	OC1D-	GGGAAGAGAAGGACATATGATCTTCATCTGCGATTACGGTACACTTT
	B63	AGTGTATCGTTTTTTTGACTAGTACATGACCACTT

175	OC1D-	GGGAAGAGAAGGACATATGATGCCTATGTGCTAGATGCAGCAGCAA
	B64	CCGCCGGCGACTGGATTGACTAGTACATGACCACTT

176	OC1D-	GGGAAGAGAAGGACATATGATCCGCGCCCTAACCTTCTGACCAAGCT
	B65	TCCCTGGCACTTGGTTGACTAGTACATGACCACTT

177	OC1D-	GGGAAGAGAAGGACATATGATCCTTATGTATTATCAGTCATACCGGA
	B66	CGCAGCCCGCTGGATTGACTAGTACATGACCACTT

178	OC1D-	GGGAAGAGAAGGACATATGATCTAATCTATACTGGCTGCTAACGCTT
	B67	TTTCTTTTCCATTTTTGACTAGTACATGACCACTT

179	OC1D-	GGGAAGAGAAGGACATATGATCAGTTTACGCGGAGTCGTTTGTGTCC
	B68	ATTTCTTCTCATTTTTGACTAGTACATGACCACTT

180	OC1D-	GGGAAGAGAAGGACATATGATTCACGTGAGATGATGTGTGTTCCTAG
	B69	TTTTATCTTGCTCTTTGACTAGTACATGACCACTT

181	OC1D-	GGGAAGAGAAGGACATATGATTCCTTGTGTACCGCTCCGAATGTGCT
	B70	CCAGCGCGCCTCGGTTGACTAGTACATGACCACTT

182	OC1D-	GGGAAGAGAAGGACATATGATAAGCCGGCCCGGGAACATGTCACGC
	B71	GCGCGCGCAAAGTAGTTGACTAGTACATGACCACTT

183	OC1D-	GGGAAGAGAAGGACATATGATCCTGGATTTCCGAAATTAGAGTGCCG
	B72	TTTCGTTACGGTTTTTGACTAGTACATGACCACTT

184	OC1D-	GGGAAGAGAAGGACATATGATCGTGTCATCCGCACAAGGAGGCCTG
	B73	CATGGCAGGGACACGTTGACTAGTACATGACCACTT

185	OC1D-	GGGAAGAGAAGGACATATGATGAGTAGACTTTTTGTATCATTTTTTTA
	B74	TCGTAAGATATTTTTGACTAGTACATGACCACTT

186	OC1D-	GGGAAGAGAAGGACATATGATCCATGTGAGATGATGTGTGTTCCTAG
	B75	TTTTATCTTGCTCTTTGACTAGTACATGACCACTT

187	OC1D-	GGGAAGAGAAGGACATATGATCTTTGCTCTAGAGTGTAGTCTATGAG
	B76	GGACAAGGTAGCCATTGACTAGTACATGACCACTT

188	OC1D-	GGGAAGAGAAGGACATATGATGTTGGTTTTCTTTCTCTTTCTTTTCTTT
	B77	CTCTTTCTATTTTTGACTAGTACATGACCACTT

189	OC1D-	GGGAAGAGAAGGACATATGATCAATCGGGCGGGGGTAAGAGGCGTG
	B78	CGCAGCGTGGAGGTGTTGACTAGTACATGACCACTT

190	OC1D-	GGGAAGAGAAGGACATATGATCACCGTGGTGCGCAAAGCCGCAACG
	B79	AGAACTGCGGAATCGTTGACTAGTACATGACCACTT

191	OC1D-	GGGAAGAGAAGGACATATGATTGCTTTAAGTCTTTTTATCATTTTGTT
	B80	TCCTTCATTTTTTTTGACTAGTACATGACCACTT

192	OC1D-	GGGAAGAGAAGGACATATGATCGACTAGTTATACTGCAAAGGCTATA
	B81	AGCGCGAGCGCGCGTTGACTAGTACATGACCACTT

193	OC1D-	GGGAAGAGAAGGACATATGATGAGTAATAGATGGCGTACACAAATC
	B82	GGATACGACGAGCGCTTGACTAGTACATGACCACTT

194	OC1D-	GGGAAGAGAAGGACATATGATTTTCGCTTCAAGATTCCCAACGCCTT
	B83	GTAAGTCAAGGTTTTTGACTAGTACATGACCACTT

195	OC1D-	GGGAAGAGAAGGACATATGATGTGTGAGATGAGCCCCTGGACCAGA
	B84	CGCACGCTCGCACTGTTGACTAGTACATGACCACTT

196	OC1D-	GGGAAGAGAAGGACATATGATCAGGATGCGGCGCCGGTAATTGACT
	B85	TCCCCCTACGTAGGATTGACTAGTACATGACCACTT

197	OC1D-	GGGAAGAGAAGGACATATGATCAGGGACCCGGCCGGTGCATCTCCTT
	B86	CTTTAGCGTACGCCTTGACTAGTACATGACCACTT

198	OC1D-	GGGAAGAGAAGGACATATGATCTGCTCTAAAGTACCAACCGCGGGA
	B87	GCTAAATGCAAGCCGTTGACTAGTACATGACCACTT

199	OC1D-	GGGAAGAGAAGGACATATGATGATTGCCATGCATTAGGGGGGGACG
	B88	CGCGCGAAAGGGAGATTGACTAGTACATGACCACTT

200	OC1D-	GGGAAGAGAAGGACATATGATTCGCTCTAAAGTACCAACCGCGGGA
	B89	GCTAAATGCAAGCCGTTGACTAGTACATGACCACTT

201	OC1D-	GGGAAGAGAAGGACATATGATAAAAAACCGGGGTTCTTAATTTTCAT
	B90	TGTTCGTCGTACTTTTGACTAGTACATGACCACTT

202	OC1D-	GGGAAGAGAAGGACATATGATAACCCATTGGTGAATCGCAACCACA
	B91	GCCAGCCCGGCGCGATTGACTAGTACATGACCACTT

203	OC1D-	GGGAAGAGAAGGACATATGATCGAAGTGAGGGGATCGCGCGGGGTG
	B92	CACCTAAATATGGGATTGACTAGTACATGACCACTT

204	OC1D-	GGGAAGAGAAGGACATATGATAGCCTTATGTACTATAGAAGTCAGCT
	B93	ATCCGCCGCACAATTTGACTAGTACATGACCACTT

205	OC1D-	GGGAAGAGAAGGACATATGATCGTTGTTTTTCCCAAAGCTCGTTAGC
	B94	ATTCATTCCTATTTTTGACTAGTACATGACCACTT

206	OC1D-	GGGAAGAGAAGGACATATGATGATCATCAGCGGAAAGCACGAAACG
	B95	CCACGGGCCGCGGCATTGACTAGTACATGACCACTT

207	OC1D-	GGGAAGAGAAGGACATATGATTCCTTCCTATTGACAATGCGCCCGGG
	B96	CCTCTTCAATTGTATTGACTAGTACATGACCACTT

208	OC1D-	GGGAAGAGAAGGACATATGATAGTTGCCGCGCGGCGCAAGATTGGA
	B97	GAGTCCCGGGCTGTATTGACTAGTACATGACCACTT

209	OC1D-	GGGAAGAGAAGGACATATGATCATAAGTTCGTTCATTCCGTTAACAC
	B98	GCGTATGGCGTTTTTTGACTAGTACATGACCACTT

210	OC1D-	GGGAAGAGAAGGACATATGATCCTTTGTCTCCAAATCTTAGGACTGA
	B99	ATGAGTGCCTATTTTTGACTAGTACATGACCACTT

211	OC1D-	GGGAAGAGAAGGACATATGATCTTCTTTGAGAATTCTCTTTTTACAAT
	B100	TCCGGCGCCGTGATTGACTAGTACATGACCACTT

212	OC1D-	GGGAAGAGAAGGACATATGATTAGGCTAACTGTTTAGGGATTTGATA
	A16	TGCATGAGGAGCACTTGACTAGTACATGACCACTT

213	OC1D-	GGGAAGAGAAGGACATATGATCGTCTGTCTTCTTCGAATACGTTTTG
	A17	GGCTAAGCCCATTTTTGACTAGTACATGACCACTT

214	OC1D-	GGGAAGAGAAGGACATATGATTAGGCTAACTGCTCAGGGATTTGATA
	A20	TGCATGAGGAGCACTTGACTAGTACATGACCACTT

215	OC1D-	GGGAAGAGAAGGACATATGATTAGGCTAACTGTTCAGGGACTTGATA
	A21	TGCATGAGGAGCACTTGACTAGTACATGACCACTT

216	OC1D-	GGGAAGAGAAGGACATATGATTAGGCTCACTGTTCAGGGATTTGATA
	A22	TGCATGAGGAGCACTTGACTAGTACATGACCACTT

217	OC1D-	GGGAAGAGAAGGACATATGATTAGGCTAACTGTTCAGGGATTTGATA
	A25	TGCATGGGGAGCACTTGACTAGTACATGACCACTT

218	OC1D-	GGGAAGAGAAGGACATATGATTTCTTCCTATTGACGATGCGCCCGGG
	A26	CCTCTTCAATTGTATTGACTAGTACATGACCACTT

219	OC1D-	GGGAAGAGAAGGACATATGATTAGGCTAACTGTTCGGGGATTTGATA
	A27	TGCATGAGGAGCACTTGACTAGTACATGACCACTT

220	OC1D-	GGGAAGAGAAGGACATATGATTAGGCTAACTGTTCAGGGATTTGATA
	A28	TGCACGAGGAGCACTTGACTAGTACATGACCACTT

221	OC1D-	GGGAAGAGAAGGACATATGATTAGGTTAACTGTTCAGGGATTTGATA
	A29	TGCATGAGGAGCACTTGACTAGTACATGACCACTT

222	OC1D-	GGGAAGAGAAGGACATATGATTAGGCTAACTGTTCAGGGATTTGATG
	A30	TGCATGAGGAGCACTTGACTAGTACATGACCACTT

112	OC1D-	GGGAAGAGAAGGACATATGATTCATGTGAGATGATGTGTGTTCCTAG
	B1 or	TTTTATCTTGCTCTTTGACTAGTACATGACCACTT
	OC1D-
	A2

113	OC1D-	GGGAAGAGAAGGACATATGATTAGGCTAACTGTTCAGGGATTTGATA
	B2 or	TGCATGAGGAGCACTTGACTAGTACATGACCACTT
	OC1D-
	A1

114	OC1D-	GGGAAGAGAAGGACATATGATCCGCTCTAAAGTACCAACCGCGGGA
	B3 or	GCTAAATGCAAGCCGTTGACTAGTACATGACCACTT
	OC1D-
	A19

115	OC1D-	GGGAAGAGAAGGACATATGATTGTGTCAGGCTCTAGAGTCTAGACGG
	B4	CCGGGGTCCCGGATTTGACTAGTACATGACCACTT

116	OC1D-	GGGAAGAGAAGGACATATGATCCTTATGTCTAGCGGCCTTACGCGAT
	B5	TAGTGGCGTTTTGTTTGACTAGTACATGACCACTT

117	OC1D-	GGGAAGAGAAGGACATATGATCTTTATGTATTATCAGTCATACCGGA
	B6	CGCAGCCCGCTGGATTGACTAGTACATGACCACTT

118	OC1D-	GGGAAGAGAAGGACATATGATTGTGTTATTACACTTCGTGATTTTCCT
	B7 or	TGCTTTTCTATTTTTGACTAGTACATGACCACTT
	OC1D-
	A3

119	OC1D-	GGGAAGAGAAGGACATATGATCCAACATCTAAAGTACTGGTCGCCTA
	B8	GGGAGACTGTTCGGTTGACTAGTACATGACCACTT

120	OC1D-	GGGAAGAGAAGGACATATGATGCTATATTCGCAAAAGCAGGCTGAG
	B9	TGCGGCAGGCGCGTGTTGACTAGTACATGACCACTT

121	OC1D-	GGGAAGAGAAGGACATATGATTCATTCATTCGCAACACAATTGTATT
	B10	CGCATCTGCGATTTTTGACTAGTACATGACCACTT

122	OC1D-	GGGAAGAGAAGGACATATGATCTTTCTCTTTTCTAATATTTAATTTAT
	B11 or	TGGGTACCAATTTTTGACTAGTACATGACCACTT
	OC1D-
	A11

123	OC1D-	GGGAAGAGAAGGACATATGATCTTTGTTTCGCATACGTTTTCTTTTTC
	B12 or	TCTCTTCTTATTTTTGACTAGTACATGACCACTT
	OC1D-
	A7

124	OC1D-	GGGAAGAGAAGGACATATGATTATTCTGTTCTTCAAAAATCTTTTAG
	B13 or	CGTATACGCTATTTTTGACTAGTACATGACCACTT
	OC1D-
	A5

125	OC1D-	GGGAAGAGAAGGACATATGATTTCCTTATGTTCGGTCAACAGGGACT
	B14	GCTGCAGCACCGGCTTGACTAGTACATGACCACTT

126	OC1D-	GGGAAGAGAAGGACATATGATTAAGCGCACTCAACAGGGTCTATGA
	B15	TCCGCGCCGATCATGTTGACTAGTACATGACCACTT

127	OC1D-	GGGAAGAGAAGGACATATGATCCGCTTTCCATTGAGATTATAAGCTG
	B16 or	TTAGAGACTTATTTTTGACTAGTACATGACCACTT
	OC1D-
	A15

128	OC1D-	GGGAAGAGAAGGACATATGATTTTCGAAACGTTTCTTTCAAGTTCTT
	B17 or	AATCATTCCCATTTTTGACTAGTACATGACCACTT
	OC1D-
	A8

129	OC1D-	GGGAAGAGAAGGACATATGATCATTAGATGCGCAGTTCGAAGCCGG
	B18	TACAGCTGGCGCGCGTTGACTAGTACATGACCACTT

130	OC1D-	GGGAAGAGAAGGACATATGATAAAGAATAACCTTAAAATAACACCA
	B19	CCGCCTCACAGCATATTGACTAGTACATGACCACTT

TABLE 4

List of truncated aptamers.

SEQ
ID
NO	Name	Sequence

223	OC1D-B1.1	ATGTGTGTTCCTAGTTTTATCTTGCTCTTTGACTA
		GTACATGACCACTTG

224	OC1D-B1.2	TTCCTAGTTTTATCTTGCTCTTTGACTAGTA

225	OC1D-B1.3	GGACATATGATTCATGTGAGA

226	OC1D-B9.1	TTCGCAAAAGCAGGCTGAGTGCGGC

227	OC1D-B9.2	CAGGCGCGTGTTGACTAGTACATGACCAC

228	OC1D-A9.1	GGGAAGAGAAGGACATATGATATTTCGTACTACTT
		TTCTTCCAA

229	OC1R-B1.1	AUGUGUGUUCCUAGUUUUAUCUUGCUCUUUGACUA
		GUACAUGACCACUUG

230	OC1R-B1.2	UUCCUAGUUUUAUCUUGCUCUUUGACUAGUA

231	OC1R-B1.3	GGACAUAUGAUUCAUGUGAGA

232	OC1R-B9.1	UUCGCAAAAGCAGGCUGAGUGCGGC

233	OC1R-B9.2	CAGGCGCGUGUUGACUAGUACAUGACCAC

234	OC1R-A9.1	GGGAAGAGAAGGACAUAUGAUAUUUCGUACUACUU
		UUCUUCCAA

TABLE 5

List of Conserved Motif Sequences

SEQ ID NO	Sequence

235	UUCCUANNUUUAUCUU

236	TTCCTANNTTTATCTT

237	UUCGCANAAG

238	UGCGGCANGCGCGU

239	TTCGCANAAG

240	TGCGGCANGCGCGT

241	CUUUUCUUCC

242	CTTTTCTTCC

243	NGCGCGCGCN

244	NGCGCGCGCN

Claims

What is claimed is:

1. An aptamer composition comprising an oligonucleotide that is at least one of deoxyribonucleotides, ribonucleotides, derivatives of deoxyribonucleotides, derivatives of ribonucleotides, or mixtures thereof; wherein the aptamer composition has a binding affinity for at least one of tooth, enamel, dentin, carbonated calcium-deficient hydroxyapatite, or mixtures thereof.

2. The aptamer composition of claim 1, wherein the aptamer composition has a binding affinity for tooth.

3. The aptamer composition of claim 1, comprising at least one oligonucleotide that has at least 50% nucleotide sequence identity to at least one of SEQ ID NO 1 to SEQ ID NO 234.

4. The aptamer composition of claim 1, comprising at least one oligonucleotide of SEQ ID NO 1 to SEQ ID NO 234.

5. The aptamer composition of claim 1, comprising an oligonucleotide that is at least one of SEQ ID NO 1, SEQ ID NO 9, SEQ ID NO 25, SEQ ID NO 112, SEQ ID NO 120, SEQ ID NO 136, or SEQ ID NO 223 to SEQ ID NO 234.

6. The aptamer composition of claim 1, wherein the oligonucleotide comprises one or more motifs that are at least one of SEQ ID NO 235, SEQ ID NO 236, SEQ ID NO 237, SEQ ID NO 238, SEQ ID NO 239, SEQ ID NO 240, SEQ ID NO 241, SEQ ID NO 242, SEQ ID NO 243, and SEQ ID NO 244.

7. The aptamer composition of claim 1, wherein the oligonucleotide comprises natural or non-natural nucleobases.

8. The aptamer composition of claim 7, wherein the non-natural nucleobases are at least one of hypoxanthine, xanthine, 7-methylguanine, 5,6-dihydrouracil, 5-5-methylcytosine, 5-hydroxymethylcytosine, thiouracil, 1-methylhypoxanthine, 6-methylisoquinoline-1-thione-2-yl, 3-methoxy-2-naphthyl, 5-propynyluracil-1-yl, 5-methylcytosin-1-yl, 2-aminoadenin-9-yl, 7-deaza-7-iodoadenin-9-yl, 7-deaza-7-propynyl-2-aminoadenin-9-yl, phenoxazinyl, phenoxazinyl-G-clam, or mixtures thereof.

9. The aptamer composition of claim 1, wherein the nucleosides of the oligonucleotide are linked by a chemical motif that is at least one of natural phosphate diester, chiral phosphorothionate, chiral methyl phosphonate, chiral phosphoramidate, chiral phosphate chiral triester, chiral boranophosphate, chiral phosphoroselenoate, phosphorodithioate, phosphorothionate amidate, methylenemethylimino, 3′-amide, 3′ achiral phosphoramidate, 3′ achiral methylene phosphonates, thioformacetal, thioethyl ether, or mixtures thereof.

10. The aptamer composition of claim 1, where the derivatives of ribonucleotides or said derivatives of deoxyribonucleotides are at least one of locked oligonucleotides, peptide oligonucleotides, glycol oligonucleotides, threose oligonucleotides, hexitol oligonucleotides, altritol oligonucleotides, butyl oligonucleotides, L-ribonucleotides, arabino oligonucleotides, 2′-fluoroarabino oligonucleotides, cyclohexene oligonucleotides, phosphorodiamidate morpholino oligonucleotides, or mixtures thereof.

11. The aptamer composition of claim 1, comprising at least one polymeric material, wherein the at least one polymeric material is covalently linked to the oligonucleotide.

12. The aptamer composition of claim 11, wherein the at least one polymeric material is polyethylene glycol.

13. The aptamer composition of claim 1, wherein the nucleotides at the 5′- and 3′-ends of the oligonucleotide are inverted.

14. The aptamer composition of claim 1, wherein at least one nucleotide of the oligonucleotide is fluorinated at the 2′ position of the pentose group.

15. The aptamer composition of claim 1, wherein pyrimidine nucleotides of the oligonucleotide are fluorinated at the 2′ position of the pentose group.

16. The aptamer composition of claim 1, wherein the oligonucleotide is covalently or non-covalently attached to at least one oral care active ingredient comprising whitening agents, brightening agents, anti-stain agents, anti-cavity agents, anti-erosion agents, anti-tartar agents, anti-calculus agents, anti-plaque agents, teeth remineralizing agents, anti-fracture agents, strengthening agents, abrasion resistance agents, anti-gingivitis agents, anti-microbial agents, anti-bacterial agents, anti-fungal agents, anti-yeast agents, anti-viral, anti-malodor agents, breath freshening agents, flavoring agents, cooling agents, taste enhancement agents, olfactory enhancement agents, anti-adherence agents, smoothness agents, surface modification agents, anti-tooth pain agents, anti-sensitivity agents, anti-inflammatory agents, gum protecting agents, periodontal actives, tissue regeneration agents, anti-blood coagulation agents, anti-clot stabilizer agents, salivary stimulant agents, salivary rheology modification agents, enhanced retention agents, soft/hard tissue targeted agents, tooth/soft tissue cleaning agents, antioxidants, pH modifying agents, H-2 antagonists, analgesics, natural extracts and essential oils, dyes, optical brighteners, cations, phosphates, fluoride ion sources, peptides, nutrients, enzymes, mouth and throat products, or mixtures thereof.

17. The aptamer composition of claim 16, wherein the oral care active ingredient is at least one of dyes or optical brighteners.

18. The aptamer composition of claim 16, wherein the oral care active ingredient is 4,4′-diamino-2,2′-stilbenedisulfonic acid.

19. The aptamer composition of claim 1, wherein the oligonucleotide is covalently or non-covalently attached to one or more nanomaterials.

20. A method for delivering one or more oral care active ingredients to the oral cavity comprising administering an oral care composition comprising at least one nucleic acid aptamer and one or more oral care active ingredients; wherein the at least one nucleic acid aptamer and said one or more oral care active ingredients are covalently or non-covalently attached; and wherein the at least one nucleic acid aptamer has a binding affinity for an oral cavity component.